var title_f9_40_9856="O2 prescription air travel";
var content_f9_40_9856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Oxygen prescription for air travel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 461px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sample oxygen prescription for air travel. Some airlines request that prescriptions be printed on physician letterhead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on information from the Airline Oxygen Council of America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9856=[""].join("\n");
var outline_f9_40_9856=null;
var title_f9_40_9857="Yellow fever vaccine: Patient drug information";
var content_f9_40_9857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Yellow fever vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     see \"Yellow fever vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/14/38117?source=see_link\">",
"     see \"Yellow fever vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      YF-VAX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      YF-VAX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_yellow_fever.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11927 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9857=[""].join("\n");
var outline_f9_40_9857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235039\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235040\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026006\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=related_link\">",
"      Yellow fever vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/14/38117?source=related_link\">",
"      Yellow fever vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_40_9858="Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Patient drug information";
var content_f9_40_9858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/32/8710?source=see_link\">",
"     see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/36/3654?source=see_link\">",
"     see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6215227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pentacel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9748134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pediacel&reg;;",
"     </li>",
"     <li>",
"      Pentacel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10024837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_multi_vaccine_infants.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12168 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9858=[""].join("\n");
var outline_f9_40_9858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215227\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9748134\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024837\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/32/8710?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/36/3654?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_40_9859="ARF LIFT";
var content_f9_40_9859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Ligation of the intersphincteric fistula procedure (LIFT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration shows the internal and external openings of the fistulous tract. A clamp in inserted under the tract and the fistula is ligated with a suture. The external opening is curetted and remains open. The lateral view shows the relationship of the ligated internal opening to the anatomy and external opening of the fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9859=[""].join("\n");
var outline_f9_40_9859=null;
var title_f9_40_9860="Calculator: PELD score for end-stage liver disease (patients less than 12 years old)";
var content_f9_40_9860=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"PELD_form\" name=\"PELD_form\" onkeydown=\"clrResults();\" onkeyup=\"PELD_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          PELDScore = 10 * ((0.480 * ln(Bilirubin)) + (1.857 * ln(INR)) - (0.687 * ln(Albumin)) + ListingAgeFactor + Growth)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sex",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Sex_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Female|1\"/>",
"              Female",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Sex_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Male|2\"/>",
"              Male",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"PELD_fx(); minMaxCheck();\" onchange=\"PELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"PELD_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"PELD_fx(); minMaxCheck();\" onchange=\"PELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"PELD_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"PELD_fx(); minMaxCheck();\" onchange=\"PELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"PELD_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Albumin",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Albumin_param\" onblur=\"PELD_fx(); minMaxCheck();\" onchange=\"PELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Albumin_unit\" onchange=\"PELD_fx();\" style=\"width:105px;\">",
"              <option value=\"0.1|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mg%\">",
"               mg%",
"              </option>",
"              <option value=\"0.001|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"0.1|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Bilirubin",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Bilirubin_param\" onblur=\"PELD_fx(); minMaxCheck();\" onchange=\"PELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Bilirubin_unit\" onchange=\"PELD_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              INR",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"INR_param\" onblur=\"PELD_fx(); minMaxCheck();\" onchange=\"PELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\">",
"             &nbsp;",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Listing",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Listing_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Age at listing 1 year or older|0\"/>",
"              Age at listing 1 year or older",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Listing_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Age at listing less than 1 year|1\"/>",
"              Age at listing less than 1 year",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Exception Diagnoses",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Exception_Diagnoses_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Non contributory|0\"/>",
"              Non contributory",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Exception_Diagnoses_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Urea cycle disorder|1\"/>",
"              Urea cycle disorder",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Exception_Diagnoses_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Organic acidemia|1\"/>",
"              Organic acidemia",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Exception_Diagnoses_radio\" onclick=\"PELD_fx();\" type=\"radio\" value=\"Hepatoblastoma|1\"/>",
"              Hepatoblastoma",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Growth Failure",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input maxlength=\"12\" name=\"growth_failure\" onfocus=\"blur();\" size=\"12\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              PELD Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"PELD_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The Pediatric End-stage Liver Disease, or",
"       <b>",
"        PELD Score",
"       </b>",
"       , is used to estimate relative",
"disease severity and likely survival of patients awaiting liver transplantation.",
"      </li>",
"      <li>",
"       The",
"       <b>",
"        Growth",
"       </b>",
"       term in the equation is set to 0.667 when the subject's height or weight is less than",
"2 S.D. below the mean values for that age.  Thus, the presence of",
"       <b>",
"        Growth Failure",
"       </b>",
"       contributes almost 7 points",
"to the PELD score.",
"      </li>",
"      <li>",
"       The",
"       <b>",
"        Listing Age Factor",
"       </b>",
"       term will be set to 0.436 if the subject is under 1 year of age, or if the",
"subject is less than 2 years old AND was listed before the age of 1 year.",
"      </li>",
"      <li>",
"       <b>",
"        Exception Diagnoses:",
"       </b>",
"       UNOS specifies urea cycle disorders, organic acidemia and hepatoblastoma",
"as exceptions to the PELD score calculation (and MELD score in patients between 12 and 17 years old).",
"For patients with these diseases, the PELD score is set at 30. Other metabolic diseases may be considered",
"for exception scores by direct petition to UNOS.",
"      </li>",
"      <li>",
"       The United Network for Organ Sharing (UNOS) keeps track of such patients, and has much more",
"information about the PELD score at file://optn.transplant.hrsa.gov/resources/",
"       <wbr>",
"       </wbr>",
"       professionalResources.asp?index=8",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9860=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function PELD_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.PELD_form){",
"",
"",
"doCalc = true;",
"if (Sex_radio[0].checked){ Sex = 1; }",
"if (Sex_radio[1].checked){ Sex = 2; }",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Albumin_param.value.indexOf(',') >= 0){ Albumin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Albumin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Albumin_unit.options[Albumin_unit.selectedIndex].value.split('|');",
"Albumin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Bilirubin_param.value.indexOf(',') >= 0){ Bilirubin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Bilirubin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Bilirubin_unit.options[Bilirubin_unit.selectedIndex].value.split('|');",
"Bilirubin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (INR_param.value.indexOf(',') >= 0){ INR_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(INR_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"INR = param_value;",
"if (Listing_radio[0].checked){ Listing = 0; }",
"if (Listing_radio[1].checked){ Listing = 1; }",
"if (Exception_Diagnoses_radio[0].checked){ Exception_Diagnoses = 0; }",
"if (Exception_Diagnoses_radio[1].checked){ Exception_Diagnoses = 1; }",
"if (Exception_Diagnoses_radio[2].checked){ Exception_Diagnoses = 1; }",
"if (Exception_Diagnoses_radio[3].checked){ Exception_Diagnoses = 1; }",
"dp = 0;",
"Age_Months =  Age * 12;",
"",
"Hgt_M =  rangeN1(n2_Height, Age_Months);",
"",
"Wgt_M =  rangeN1(n2_Weight, Age_Months);",
"",
"Hgt_F =  rangeN1(n1_Height, Age_Months);",
"",
"Wgt_F =  rangeN1(n1_Weight, Age_Months);",
"",
"Listing_Age_Factor = 0;",
"if (Age_Months < 12) Listing_Age_Factor = 0.436;",
"if ((Age_Months < 24) && (Listing == 1)) Listing_Age_Factor = 0.436;",
"Growth = 0;",
"if ((Sex == 1) && doCalc){",
"if ((Height >= Hgt_F) && (Weight >= Wgt_F)) growth_failure.value = \"None\";",
"if ((Height >= Hgt_F) && (Weight < Wgt_F)){ growth_failure.value = \"Wgt alone\"; Growth = 0.6672; }",
"if ((Height < Hgt_F) && (Weight >= Wgt_F)){ growth_failure.value = \"Hgt alone\"; Growth = 0.6672; }",
"if ((Height < Hgt_F) && (Weight < Wgt_F)){ growth_failure.value = \"Hgt and Wgt\"; Growth = 0.6672; }",
"}",
"if ((Sex == 2) && doCalc){",
"if ((Height >= Hgt_M) && (Weight >= Wgt_M)) growth_failure.value = \"None\";",
"if ((Height >= Hgt_M) && (Weight < Wgt_M)){ growth_failure.value = \"Wgt alone\"; Growth = 0.6672; }",
"if ((Height < Hgt_M) && (Weight >= Wgt_M)){ growth_failure.value = \"Hgt alone\"; Growth = 0.6672; }",
"if ((Height < Hgt_M) && (Weight < Wgt_M)){ growth_failure.value = \"Hgt and Wgt\"; Growth = 0.6672; }",
"}",
"PELD_Score =  10 * ((0.480 * ln(Bilirubin)) + (1.857 * ln(INR)) - (0.687 * ln(Albumin)) + Listing_Age_Factor + Growth);",
"",
"if (doCalc) PELD_Score_param.value = fixDP(PELD_Score, dp);",
"",
"",
"",
"if (Exception_Diagnoses){",
"alert('Because of this specific disease, the PELD Score is set at 30');",
"PELD_Score_param.value = '30';",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PELD_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 11.99) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 11.99 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Albumin_param.value && Albumin < 1) {",
"Albumin = 0;",
"Albumin_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Albumin is 1 gm/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Albumin_param.value && Albumin > 1000) {",
"Albumin_param.value = \"\";",
"clrResults();",
"Albumin = 0;",
"doCalc = false;",
"alert(\"The maximum value for Albumin is 1000 gm/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin < 1) {",
"Bilirubin = 0;",
"Bilirubin_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Bilirubin is 1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin > 1000) {",
"Bilirubin_param.value = \"\";",
"clrResults();",
"Bilirubin = 0;",
"doCalc = false;",
"alert(\"The maximum value for Bilirubin is 1000 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR < 1) {",
"INR = 0;",
"INR_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for INR is 1 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR > 1000) {",
"INR_param.value = \"\";",
"clrResults();",
"INR = 0;",
"doCalc = false;",
"alert(\"The maximum value for INR is 1000 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PELD_form){",
"",
"growth_failure.value = '';",
"PELD_Score_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"n1_Height = new Array;",
"n1_Weight = new Array;",
"",
"n1_Height[0] = 45.5600; n1_Weight[0] = 2.2000; ",
"n1_Height[1] = 54.5200; n1_Weight[1] = 3.9200; ",
"n1_Height[2] = 60.6200; n1_Weight[2] = 5.4600; ",
"n1_Height[3] = 64.9400; n1_Weight[3] = 6.6600; ",
"n1_Height[4] = 68.6200; n1_Weight[4] = 7.4000; ",
"n1_Height[5] = 71.9000; n1_Weight[5] = 7.9600; ",
"n1_Height[6] = 74.7600; n1_Weight[6] = 8.4600; ",
"n1_Height[7] = 77.4400; n1_Weight[7] = 8.9800; ",
"n1_Height[8] = 78.0000; n1_Weight[8] = 9.4600; ",
"n1_Height[9] = 80.2800; n1_Weight[9] = 9.8800; ",
"n1_Height[10] = 82.4200; n1_Weight[10] = 10.3200; ",
"n1_Height[11] = 84.5200; n1_Weight[11] = 10.7800; ",
"n1_Height[12] = 86.4800; n1_Weight[12] = 11.1400; ",
"n1_Height[13] = 88.3200; n1_Weight[13] = 11.5200; ",
"n1_Height[14] = 90.1200; n1_Weight[14] = 11.9200; ",
"n1_Height[15] = 91.9000; n1_Weight[15] = 12.2000; ",
"n1_Height[16] = 93.5600; n1_Weight[16] = 12.6000; ",
"n1_Height[17] = 95.1000; n1_Weight[17] = 12.8800; ",
"n1_Height[18] = 96.6000; n1_Weight[18] = 13.1800; ",
"n1_Height[19] = 98.1000; n1_Weight[19] = 13.4600; ",
"n1_Height[20] = 99.5800; n1_Weight[20] = 13.8400; ",
"n1_Height[21] = 100.9400; n1_Weight[21] = 14.1000; ",
"n1_Height[22] = 102.2800; n1_Weight[22] = 14.4400; ",
"n1_Height[23] = 103.5200; n1_Weight[23] = 14.6800; ",
"n1_Height[24] = 104.7600; n1_Weight[24] = 14.9800; ",
"n1_Height[25] = 106.0800; n1_Weight[25] = 15.2800; ",
"n1_Height[26] = 107.2000; n1_Weight[26] = 15.6400; ",
"n1_Height[27] = 108.4000; n1_Weight[27] = 15.9800; ",
"n1_Height[28] = 109.6200; n1_Weight[28] = 16.3000; ",
"n1_Height[29] = 110.8400; n1_Weight[29] = 16.6800; ",
"n1_Height[30] = 111.9600; n1_Weight[30] = 17.1200; ",
"n1_Height[31] = 113.0800; n1_Weight[31] = 17.4400; ",
"n1_Height[32] = 114.3200; n1_Weight[32] = 17.8400; ",
"n1_Height[33] = 115.4600; n1_Weight[33] = 18.3200; ",
"n1_Height[34] = 116.7200; n1_Weight[34] = 18.7800; ",
"n1_Height[35] = 118.0000; n1_Weight[35] = 19.2400; ",
"n1_Height[36] = 119.1800; n1_Weight[36] = 19.7600; ",
"n1_Height[37] = 120.4800; n1_Weight[37] = 20.2000; ",
"n1_Height[38] = 121.8200; n1_Weight[38] = 20.8200; ",
"n1_Height[39] = 123.2600; n1_Weight[39] = 21.3400; ",
"n1_Height[40] = 124.6400; n1_Weight[40] = 21.8600; ",
"n1_Height[41] = 126.1400; n1_Weight[41] = 22.4800; ",
"n1_Height[42] = 127.6600; n1_Weight[42] = 23.1200; ",
"n1_Height[43] = 129.2200; n1_Weight[43] = 23.7600; ",
"n1_Height[44] = 130.9200; n1_Weight[44] = 24.5000; ",
"n1_Height[45] = 132.6400; n1_Weight[45] = 25.1800; ",
"n1_Height[46] = 134.4000; n1_Weight[46] = 25.8600; ",
"n1_Height[47] = 136.1800; n1_Weight[47] = 26.6600; ",
"n1_Height[48] = 137.8600; n1_Weight[48] = 27.4000; ",
"",
"function rangeN1(thisp, thisx){",
"var xconv = (thisx - 0) / 3;",
"x1 = Math.floor(xconv + .001);  ",
"return thisp[x1];",
"}",
"",
"n2_Height = new Array;",
"n2_Weight = new Array;",
"",
"n2_Height[0] = 46.0200; n2_Weight[0] = 2.4800; ",
"n2_Height[1] = 55.8000; n2_Weight[1] = 4.1000; ",
"n2_Height[2] = 62.4000; n2_Weight[2] = 5.8400; ",
"n2_Height[3] = 67.0200; n2_Weight[3] = 7.2600; ",
"n2_Height[4] = 70.7000; n2_Weight[4] = 8.1600; ",
"n2_Height[5] = 73.7000; n2_Weight[5] = 8.7200; ",
"n2_Height[6] = 76.3200; n2_Weight[6] = 9.1400; ",
"n2_Height[7] = 78.6400; n2_Weight[7] = 9.4800; ",
"n2_Height[8] = 79.2400; n2_Weight[8] = 9.6400; ",
"n2_Height[9] = 81.3800; n2_Weight[9] = 10.1000; ",
"n2_Height[10] = 83.3600; n2_Weight[10] = 10.5800; ",
"n2_Height[11] = 85.3600; n2_Weight[11] = 11.0800; ",
"n2_Height[12] = 87.2800; n2_Weight[12] = 11.4000; ",
"n2_Height[13] = 89.1400; n2_Weight[13] = 11.8200; ",
"n2_Height[14] = 91.0000; n2_Weight[14] = 12.1600; ",
"n2_Height[15] = 92.6800; n2_Weight[15] = 12.5200; ",
"n2_Height[16] = 94.3800; n2_Weight[16] = 12.9000; ",
"n2_Height[17] = 96.0800; n2_Weight[17] = 13.2800; ",
"n2_Height[18] = 97.7200; n2_Weight[18] = 13.6800; ",
"n2_Height[19] = 99.2600; n2_Weight[19] = 14.0600; ",
"n2_Height[20] = 100.7000; n2_Weight[20] = 14.4600; ",
"n2_Height[21] = 102.1600; n2_Weight[21] = 14.8600; ",
"n2_Height[22] = 103.6200; n2_Weight[22] = 15.2600; ",
"n2_Height[23] = 105.0000; n2_Weight[23] = 15.6600; ",
"n2_Height[24] = 106.3800; n2_Weight[24] = 16.0400; ",
"n2_Height[25] = 107.6600; n2_Weight[25] = 16.4000; ",
"n2_Height[26] = 109.0400; n2_Weight[26] = 16.7600; ",
"n2_Height[27] = 110.2200; n2_Weight[27] = 17.2200; ",
"n2_Height[28] = 111.5000; n2_Weight[28] = 17.6400; ",
"n2_Height[29] = 112.6800; n2_Weight[29] = 17.9400; ",
"n2_Height[30] = 113.9600; n2_Weight[30] = 18.3200; ",
"n2_Height[31] = 115.1400; n2_Weight[31] = 18.7800; ",
"n2_Height[32] = 116.3000; n2_Weight[32] = 19.1000; ",
"n2_Height[33] = 117.4600; n2_Weight[33] = 19.5000; ",
"n2_Height[34] = 118.6000; n2_Weight[34] = 19.8600; ",
"n2_Height[35] = 119.7200; n2_Weight[35] = 20.2000; ",
"n2_Height[36] = 120.8400; n2_Weight[36] = 20.5200; ",
"n2_Height[37] = 121.9600; n2_Weight[37] = 20.9000; ",
"n2_Height[38] = 123.0400; n2_Weight[38] = 21.2800; ",
"n2_Height[39] = 124.1200; n2_Weight[39] = 21.7400; ",
"n2_Height[40] = 125.2800; n2_Weight[40] = 22.1000; ",
"n2_Height[41] = 126.4000; n2_Weight[41] = 22.6400; ",
"n2_Height[42] = 127.5200; n2_Weight[42] = 23.0800; ",
"n2_Height[43] = 128.7200; n2_Weight[43] = 23.6000; ",
"n2_Height[44] = 129.8800; n2_Weight[44] = 24.1400; ",
"n2_Height[45] = 131.0200; n2_Weight[45] = 24.7800; ",
"n2_Height[46] = 132.2400; n2_Weight[46] = 25.4000; ",
"n2_Height[47] = 133.4200; n2_Weight[47] = 26.0600; ",
"n2_Height[48] = 134.6800; n2_Weight[48] = 26.8200; ",
"",
"function rangeN2(thisp, thisx){",
"var xconv = (thisx - 0) / 3;",
"x1 = Math.floor(xconv + .001);  ",
"return thisp[x1];",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f9_40_9860=null;
var title_f9_40_9861="Velamentous cord insertion twin pregnancy";
var content_f9_40_9861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Velamentous cord insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diamnionic, monochorionic twin placenta with the intervening amnion rolled in the center. Notice the haphazard vascularization (large arrow). The velamentous cord insertion (small arrow) of the smaller twin of this discordant pair is not an unusual finding in monochorionic twins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mhairi G. MacDonald, Mary M. K. Seshia, et al. Avery's Neonatology Pathophysiology &amp; Management of the Newborn, 6th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9861=[""].join("\n");
var outline_f9_40_9861=null;
var title_f9_40_9862="Leukoencephalopathy due to heroin inhalation (chasing the dragon)";
var content_f9_40_9862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Leukoencephalopathy due to heroin inhalation (chasing the dragon)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9862/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9862/contributors\">",
"     Amy T Waldman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9862/contributors\">",
"     Alan K Percy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9862/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9862/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9862/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9862/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/40/9862/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although heroin use by inhalation (\"chasing the dragon\") first developed in the 1950s [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/1\">",
"     1",
"    </a>",
"    ], the leukoencephalopathy and neurologic symptoms associated with this method of heroin abuse were initially described in 1982 in a report from the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Chasing the dragon\" is a method of heroin vapor inhalation that is distinct from smoking or sniffing heroin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Other names for this process include \"chinesing\" and \"Chinese blowing.\" A small amount of heroin powder is placed on aluminum foil, which is heated by placing a match or lighter underneath. The white powder becomes a reddish-brown gelatinous substance that releases a thick, white smoke, which resembles a dragon's tail. The fumes are \"chased\" or inhaled through a straw or small tube [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the pathogenesis, clinical features, diagnosis, and management of heroin leukoencephalopathy from chasing the dragon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of neurologic injury related to heroin inhalation is unknown. Since heroin leukoencephalopathy has not been observed in users who inject or snort heroin, it is possible that unknown toxins contained in the heroin pyrolysate (the product of chemical change caused by heating) are responsible for the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the disease was not replicated in rats exposed to this compound [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2\">",
"     2",
"    </a>",
"    ]. Triethyl tin (TET), a component of inorganic tin, was also suspected since TET poisoning results in vacuolar white matter edema [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3,5\">",
"     3,5",
"    </a>",
"    ], but an etiologic role for TET is unlikely, since the TET content in aluminum foil is negligible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitochondrial dysfunction may play a role in the development of heroin leukoencephalopathy, as suggested by mitochondrial changes on specimens from brain biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2\">",
"     2",
"    </a>",
"    ], by elevated lactate on magnetic resonance spectroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ], and by the clinical improvement with antioxidant therapy that has been reported in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In this syndrome, parkinsonian symptoms may be caused by reversible inhibition of tetrahydrobiopterin metabolism; tetrahydrobiopterin is required for the conversion of tyrosine to levodopa, the precursor of dopamine, and for the conversion of tryptophan to serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the prevalence of heroin abuse, fewer than 100 cases had been reported by the year 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial cohort of 47 heroin vapor inhalers from the Netherlands, which remains the largest report in the literature, the leukoencephalopathy occurred in three stages [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial symptoms (in order of decreasing frequency) were",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Soft/pseudobulbar",
"      </span>",
"      speech",
"     </li>",
"     <li>",
"      Cerebellar ataxia",
"     </li>",
"     <li>",
"      Motor restlessness",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Apathy/abulia/bradyphrenia",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After two to four weeks, approximately half of the patients progressed to the second (intermediate) stage, which was characterized by rapid worsening of cerebellar symptoms and additional features:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pyramidal tract signs",
"     </li>",
"     <li>",
"      Hyperactive reflexes",
"     </li>",
"     <li>",
"      Spastic hemiplegia or quadriplegia",
"     </li>",
"     <li>",
"      Tremor and myoclonus",
"     </li>",
"     <li>",
"      Chorea and athetosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A few weeks later, one-fourth of the initial cohort entered the terminal stage and developed the following symptoms before death ensued:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      \"Stretching spasms\"",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Hypotonic/areflexic",
"      </span>",
"      paresis",
"     </li>",
"     <li>",
"      Akinetic mutism",
"     </li>",
"     <li>",
"      Central pyrexia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a later report from the United States of three patients with heroin leukoencephalopathy, two were symptomatic, one with dysmetria, abulia, decorticate posturing, and progressive quadriparesis, and a second with a progressive cerebellar syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ]. A third patient, who sought medical help when his friends became ill, was asymptomatic except for signs on examination that suggested mild cerebellar involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various features of parkinsonism, in some cases reversible, may be seen as early or late manifestations of heroin leukoencephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]. These may include bradykinesia, tremor, chorea, short fenestrating steps, masked facies, soft speech, cogwheel rigidity, and loss of postural reflexes.",
"   </p>",
"   <p>",
"    The severity of disease probably depends on the amount of heroin inhaled. As an example, a patient who had inhaled 40 to 50 mg of heroin daily for three weeks prior to her hospitalization was unable to perform activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ]. Other patients developed milder symptoms with occasional use.",
"   </p>",
"   <p>",
"    Once symptoms develop, progression of disease can continue for a few weeks up to six months in the absence of continued exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ], a phenomenon called \"coasting\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain magnetic resonance imaging (MRI) shows diffuse, symmetrical white matter hyperintensities on T2, and fluid-attenuated inversion recovery (FLAIR) sequences in the cerebellum, posterior cerebrum, and posterior limbs of the internal capsule. There can be additional signal abnormalities in the splenium of the corpus callosum, the corticospinal tracts, and the lemniscal pathway in the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]. Increased signal in periventricular white matter may be present on diffusion-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A posterior-anterior gradient is typically seen in the supratentorial white matter, and the frontal lobes are therefore relatively spared [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ]. However, with significant heroin abuse, there may be frontal lobe involvement.",
"   </p>",
"   <p>",
"    Magnetic resonance spectroscopy (MRS) abnormalities in three patients with heroin leukoencephalopathy included abnormally elevated lactate in the affected white matter and decreased levels of N-acetyl aspartate in the white matter, gray matter, and cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalography in two severely affected patients showed moderate diffuse slowing with excess delta, consistent with a global encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuropathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic data from autopsy cases as well as brain biopsies reveal spongiform degeneration with relative sparing of subcortical U-fibers, vacuole formation in oligodendroglia, and myelin sheaths visible with electron microscopy. Axons are typically spared, and demyelination is not a prominent feature. The deep white matter is edematous, but inflammation is absent. Mitochondria are also abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of heroin inhalation leukoencephalopathy is clinical and should be suspected in patients with a history of chasing the dragon who present with acute or subacute onset of neurologic abnormalities. These may include one or more of the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2,3,10\">",
"     2,3,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebellar, pyramidal, or extrapyramidal signs",
"     </li>",
"     <li>",
"      Neurobehavioral changes, including confusion,",
"      <span class=\"nowrap\">",
"       apathy/abulia,",
"      </span>",
"      or motor restlessness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis is supported by the characteristic neuroimaging findings. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Diagnostic uncertainty is increased when the method of heroin abuse or history of exposure is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heroin addiction has been associated with a number of neurologic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/7\">",
"     7",
"    </a>",
"    ], including brain abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/13\">",
"     13",
"    </a>",
"    ], transverse myelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/14\">",
"     14",
"    </a>",
"    ], neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], and rhabdomyolysis with myoglobinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, these disorders are not likely to be confused with leukoencephalopathy.",
"   </p>",
"   <p>",
"    In contrast, leukoencephalopathy may occur after global anoxic-ischemic injury or after toxic exposure to a variety of agents, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antineoplastic agents (cranial irradiation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      , levamisole,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      , interleukin-2, interferon alfa)",
"     </li>",
"     <li>",
"      Immunosuppressive drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antimicrobial agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=see_link\">",
"       hexachlorophene",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drugs of abuse (toluene, ethanol, cocaine, 3,4-methylenedioxymethamphetamine, intravenous heroin, inhaled heroin pyrolysate, psilocybin)",
"     </li>",
"     <li>",
"      Environmental toxins (carbon monoxide, arsenic, carbon tetrachloride)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anoxic-ischemic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Global anoxia or ischemia, which can be precipitated by drug overdose or cardiopulmonary arrest, typically affects the gray matter in the cerebral cortex and various subcortical structures, such as the globus pallidus, with the cerebellum less frequently involved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebral white matter damage may occur with anoxic-ischemic injury, particularly after prolonged hypoxia and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/21\">",
"     21",
"    </a>",
"    ]. The radiologic appearance of white matter damage may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/22\">",
"     22",
"    </a>",
"    ]. Nevertheless, there are reports of early preferential involvement of white matter after anoxic-ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In addition, drug overdose from intravenous heroin use has been reported as a cause of anoxic&ndash;ischemic leukoencephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Drugs of abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying degrees of white matter injury may be found in chronic abusers of alcohol and toluene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic alcohol abuse is associated with white matter damage. Alcohol abusers, including those with liver disease and Wernicke encephalopathy, lose a disproportionate amount of subcortical white matter compared with cortical gray matter. Marchiafava-Bignami disease is a rare disorder of demyelination or necrosis of the corpus callosum and adjacent subcortical white matter that occurs predominantly in malnourished alcoholics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the chronic neurologic complications of alcohol\", section on 'Marchiafava-Bignami disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic toluene abuse from inhalation of vapor in glue (\"glue sniffing\"), paint, and paint thinner is associated with neurologic impairment, including dementia and selective white matter injury [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/25\">",
"       25",
"      </a>",
"      ]. Widespread white matter hyperintensity is seen on brain magnetic resonance imaging (MRI) in severely affected patients with toluene leukoencephalopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=see_link\">",
"       \"Inhalant abuse in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A case report described a severe diffuse leukoencephalopathy that followed methylenedioxymethamphetamine (MDMA, also called ecstasy) use and respiratory insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the relative contribution of anoxic-ischemic injury compared with the leukoencephalopathy is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no treatment for heroin leukoencephalopathy. As noted above, in the original cohort of 47 patients, the mortality was 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/2\">",
"     2",
"    </a>",
"    ]. Death was primarily due to respiratory failure. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Empiric antioxidant therapy (with either coenzyme Q10 [300 mg four times a day] alone, or coenzyme Q10 in combination with vitamin E [2000 mg daily] and vitamin C [2000 mg daily]) was used for two patients, with delayed but gradual improvement in one, and transient improvement correlating with treatment compliance in another [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9862/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, the absence of proven treatment, and the low likelihood of serious side effects, we suggest antioxidant therapy with the combination of coenzyme Q10, vitamin C, and vitamin E for patients with heroin leukoencephalopathy.",
"   </p>",
"   <p>",
"    Patients who survive often require physical and drug rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Chasing the dragon\" is a method of heroin vapor inhalation that is distinct from smoking or sniffing heroin and is associated with leukoencephalopathy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of neurologic injury related to heroin inhalation is unknown; toxins contained in the heroin pyrolysate may be responsible for the condition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial symptoms of heroin leukoencephalopathy include soft speech, ataxia, motor restlessness, bradyphrenia, and",
"      <span class=\"nowrap\">",
"       apathy/abulia.",
"      </span>",
"      Some patients develop progressive disease with later occurrence of pyramidal signs, hyperactive reflexes, pseudobulbar palsy, spastic paresis, tremor, myoclonus, chorea, and athetosis. Severe disease is characterized by fever, akinetic mutism, spasms, hypotonia, areflexia, and death. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain MRI shows diffuse, symmetrical white matter hyperintensities on T2 and FLAIR sequences. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropathology reveals spongiform degeneration with relative sparing of subcortical U-fibers; demyelination is not a prominent feature. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neuropathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of heroin inhalation leukoencephalopathy is clinical, and is supported by the characteristic neuroimaging findings. The differential diagnosis includes leukoencephalopathy following global anoxic-ischemic injury or exposure to other drugs of abuse. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there is no proven treatment for heroin leukoencephalopathy, we suggest antioxidant therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The suggested regimen is coenzyme Q10 (300 mg four times a day), vitamin E (2000 mg daily), and vitamin C (2000 mg daily). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/1\">",
"      Strang J, Griffiths P, Gossop M. Heroin smoking by 'chasing the dragon': origins and history. Addiction 1997; 92:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/2\">",
"      Wolters EC, van Wijngaarden GK, Stam FC, et al. Leucoencephalopathy after inhaling \"heroin\" pyrolysate. Lancet 1982; 2:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/3\">",
"      Kriegstein AR, Shungu DC, Millar WS, et al. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (\"chasing the dragon\"). Neurology 1999; 53:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/4\">",
"      Keogh CF, Andrews GT, Spacey SD, et al. Neuroimaging features of heroin inhalation toxicity: \"chasing the dragon\". AJR Am J Roentgenol 2003; 180:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/5\">",
"      Squibb RE, Carmichael NG, Tilson HA. Behavioral and neuromorphological effects of triethyl tin bromide in adult rats. Toxicol Appl Pharmacol 1980; 55:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/6\">",
"      Heales S, Crawley F, Rudge P. Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency. Mov Disord 2004; 19:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/7\">",
"      Hill MD, Cooper PW, Perry JR. Chasing the dragon--neurological toxicity associated with inhalation of heroin vapour: case report. CMAJ 2000; 162:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/8\">",
"      Sempere AP, Posada I, Ramo C, Cabello A. Spongiform leucoencephalopathy after inhaling heroin. Lancet 1991; 338:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/9\">",
"      Berger AR, Schaumburg HH, Schroeder C, et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 1992; 42:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/10\">",
"      Long H, Deore K, Hoffman RS, Nelson LS. A fatal case of spongiform leukoencephalopathy linked to \"chasing the dragon\". J Toxicol Clin Toxicol 2003; 41:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/11\">",
"      Weber W, Henkes H, M&ouml;ller P, et al. Toxic spongiform leucoencephalopathy after inhaling heroin vapour. Eur Radiol 1998; 8:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/12\">",
"      McKinney AM, Kieffer SA, Paylor RT, et al. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 2009; 193:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/13\">",
"      Hershewe GL, Davis LE, Bicknell JM. Primary cerebellar brain abscess from nocardiosis in a heroin addict. Neurology 1988; 38:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/14\">",
"      Richter RW, Rosenberg RN. Transverse myelitis associated with heroin addiction. JAMA 1968; 206:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/15\">",
"      Amnueilaph R, Boongird P, Leechawengwongs M, Vejjajiva A. Heroin neuropathy. Lancet 1973; 1:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/16\">",
"      Loizou LA, Boddie HG. Polyradiculoneuropathy associated with heroin abuse. J Neurol Neurosurg Psychiatry 1978; 41:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/17\">",
"      Schreiber SN, Liebowitz MR, Bernstein LH, Srinivasan K. Limb compression and renal impairment (crush syndrome) complicating narcotic overdose. N Engl J Med 1971; 284:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/18\">",
"      de Gans J, Stam J, van Wijngaarden GK. Rhabdomyolysis and concomitant neurological lesions after intravenous heroin abuse. J Neurol Neurosurg Psychiatry 1985; 48:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/19\">",
"      Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 2001; 345:425.",
"     </a>",
"    </li>",
"    <li>",
"     Meyer, A. Intoxication. In: Greenfield's Neuropathology, Blackwood W, McMenemey, WH, Meyer, A, et al (Eds), Williams &amp; Wilkins, Baltimore 1967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/21\">",
"      Ginsberg MD, Hedley-Whyte ET, Richardson EP Jr. Hypoxic-ischemic leukoencephalopathy in man. Arch Neurol 1976; 33:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/22\">",
"      Sawada H, Udaka F, Seriu N, et al. MRI demonstration of cortical laminar necrosis and delayed white matter injury in anoxic encephalopathy. Neuroradiology 1990; 32:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/23\">",
"      Chalela JA, Wolf RL, Maldjian JA, Kasner SE. MRI identification of early white matter injury in anoxic-ischemic encephalopathy. Neurology 2001; 56:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/24\">",
"      Molloy S, Soh C, Williams TL. Reversible delayed posthypoxic leukoencephalopathy. AJNR Am J Neuroradiol 2006; 27:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/25\">",
"      Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. J Neuropathol Exp Neurol 2004; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/26\">",
"      Bertram M, Egelhoff T, Schwarz S, Schwab S. Toxic leukencephalopathy following \"ecstasy\" ingestion. J Neurol 1999; 246:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9862/abstract/27\">",
"      Kriegstein AR, Armitage BA, Kim PY. Heroin inhalation and progressive spongiform leukoencephalopathy. N Engl J Med 1997; 336:589.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1696 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9862=[""].join("\n");
var outline_f9_40_9862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuropathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anoxic-ischemic injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=related_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_40_9863="Evaluation and management of ruptured ovarian cyst";
var content_f9_40_9863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of ruptured ovarian cyst",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9863/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9863/contributors\">",
"     Andrew N Blechman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9863/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9863/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9863/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9863/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9863/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/40/9863/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an ovarian cyst is a common occurrence in women of reproductive age. Management is based upon patient characteristics, including the severity of symptoms, whether there is hemodynamic instability, and the presumptive histological diagnosis. The majority of women are stable and managed as outpatients, with analgesics and rest.",
"   </p>",
"   <p>",
"    Evaluation and management of women with a ruptured ovarian cyst are reviewed here. The evaluation and management of adnexal masses that are not ruptured is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an ovarian cyst may be asymptomatic or associated with the sudden onset of unilateral lower abdominal pain. The pain often begins during strenuous physical activity, such as exercise or sexual intercourse. It may be accompanied by light vaginal bleeding due to a drop in secretion of ovarian hormones and subsequent endometrial sloughing.",
"   </p>",
"   <p>",
"    Blood from the rupture site may seep into the ovary, which can cause pain from stretching of the ovarian cortex, or it may flow into the abdomen, which has an irritant effect on the peritoneum. However, it is also possible for large amounts of blood to be present in the abdomen without producing symptoms. The risk and magnitude of bleeding associated with hemorrhagic ovarian cysts is increased in women with a congenital or acquired bleeding diatheses and in those taking anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serous or mucinous fluid released upon cyst rupture is not very irritating; the patient may remain asymptomatic despite accumulation of a large volume of intraperitoneal fluid. On the other hand, spillage of sebaceous material upon rupture of a dermoid cyst causes a marked granulomatous reaction and chemical peritonitis, which is usually quite painful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs are usually in the normal range, although a low-grade fever may be present. Significant hemorrhage leading to shock is rare. Paradoxically, some women with acute hemoperitoneum and hypotension may not show tachycardia or may display bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One side of the lower abdomen is often tender to palpation. The right lower quadrant is most commonly affected, possibly because the rectosigmoid colon protects the left ovary from the effects of abdominal trauma. Rupture of a simple cyst usually results in only mild to moderate tenderness on deep palpation. If the cyst has not completely collapsed, an adnexal mass may be palpable on bimanual examination. At the other end of the spectrum, release of sebaceous material or blood into the abdomen may cause overt peritonitis with rigidity of the abdominal wall and rebound tenderness. Cervical motion tenderness may also be present.",
"   </p>",
"   <p>",
"    Intraabdominal hemorrhage may be associated with Cullen's sign (ie, periumbilical ecchymoses).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goals in the evaluation of women with suspected rupture of an ovarian cyst are to exclude ruptured ectopic pregnancy, which has a similar clinical presentation, and to determine whether the patient can be safely managed expectantly or whether surgical intervention is needed.",
"   </p>",
"   <p>",
"    The past medical and surgical histories should be reviewed for potential gynecologic causes of lower abdominal pain: history of or risk factors for ovarian cysts, endometriosis, pelvic inflammatory disease, endometritis, or leiomyomas (see individual topic reviews). A careful history of medication use is important, including prescribed medications, over-the-counter medications, and herbal products. Drug ingestion may be associated with a bleeding diathesis via a variety of mechanisms, such as the induction or exacerbation of thrombocytopenia or platelet dysfunction, aplastic anemia, or vascular purpura. Anticoagulation may predispose to corpus luteum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the possibility of pregnancy (ectopic, intrauterine, or heterotopic) and nongynecological causes of pain (appendicitis, diverticular disease, bowel obstruction, renal calculi) should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40323?source=see_link\">",
"     \"History and physical examination in adults with abdominal pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory and imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum or urine pregnancy testing (human chorionic gonadotropin [hCG]) &mdash; If the hCG is elevated, then the patient must be evaluated for ectopic pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete blood count with differential &mdash; A low hematocrit may be caused by hemorrhage or baseline anemia, although the initial hematocrit may be normal or mildly decreased with acute blood loss. Severe thrombocytopenia can worsen bleeding associated with cyst rupture. The white blood cell count is typically normal or only mildly elevated with cyst rupture; therefore, leukocytosis or left shift should raise suspicion of an infectious or necrotic process.",
"     </li>",
"     <li>",
"      Blood type and crossmatch is indicated in patients with peritoneal signs or hemodynamic instability.",
"     </li>",
"     <li>",
"      Urinalysis &mdash; Urinalysis is usually normal, but pyuria may occur if the urinary system becomes inflamed from an adjacent adnexal process, such as a ruptured ovarian cyst. Hematuria suggests the presence of a stone or infection.",
"     </li>",
"     <li>",
"      Blood and urine cultures and cervical studies for sexually transmitted infections should be obtained from patients with concomitant fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneal symptoms to rule out pelvic or urinary tract infection.",
"     </li>",
"     <li>",
"      Ultrasound examination is the cornerstone of the evaluation because it is readily available, inexpensive, and is a sensitive method for diagnosing ovarian cysts. Sonographic findings of an adnexal mass and fluid in the pelvis suggest a ruptured ovarian cyst, but are not diagnostic. Bleeding from an ectopic pregnancy, ascites associated with an ovarian fibroma or cancer, or pus from a tuboovarian abscess can have a similar appearance. Rupture of cyst contents typically yields only a small pool of peritoneal fluid, but large amounts of fluid may be present if rupture is accompanied by hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preoperative sonography may show features suggestive of malignancy or a specific pathology (eg, dermoid cyst). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest computed tomography (CT) if the diagnosis is unclear after ultrasound examination, particularly if the patient has severe symptoms suggestive of a nongynecologic process (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75150 \" href=\"UTD.htm?36/3/36913\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72345 \" href=\"UTD.htm?1/63/2034\">",
"     image 2",
"    </a>",
"    ). CT can improve identification of the ovary, which can be difficult to delineate if obscured by blood clots in the adnexa. Blood clots may be interpreted as a mixed solid and cystic ovarian mass, or a solid ovarian mass. Hounsfield units (a quantitative scale for describing radiodensity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/8\">",
"     8",
"    </a>",
"    ]) of the fluid may help differentiate blood from mucinous or serous fluid in the posterior cul-de-sac (pouch of Douglas).",
"   </p>",
"   <p>",
"    We suggest avoiding diagnostic paracentesis or culdocentesis to look for blood or other fluids, given that noninvasive imaging studies have high sensitivity for the demonstration of intraperitoneal free fluid (range 84 to 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. We also do not feel it is essential to determine whether the fluid collection is serous or blood since the presence of fluid alone is not an indication for emergency operative intervention in a hemodynamically stable patient.",
"   </p>",
"   <p>",
"    We do not test for ovarian tumor markers, such as serum CA 125 and CA 19-9, as they may be elevated with hemoperitoneum or irritation of the peritoneum by cyst contents, as well as a number of other benign conditions (",
"    <a class=\"graphic graphic_table graphicRef81621 \" href=\"UTD.htm?12/48/13069\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary gynecological disorders in differential diagnosis are discussed below. The differential diagnosis of nongynecological causes of abdominal pain are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mittelschmerz &mdash; Mittelschmerz (German for \"middle pain\") refers to midcycle pain in an ovulatory woman caused by normal follicular enlargement just prior to ovulation or to normal follicular bleeding at ovulation. The pain is typically mild and unilateral; it occurs midway between menstrual periods and lasts for a few hours to a couple of days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"       \"Physiology of the normal menstrual cycle\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ectopic pregnancy &mdash; Ectopic pregnancy has clinical symptoms and sonographic features similar to those of a ruptured ovarian cyst. In women with acute pelvic pain or abnormal vaginal bleeding, a positive pregnancy test strongly suggests the presence of an ectopic pregnancy if an intrauterine pregnancy cannot be visualized sonographically. If an intrauterine pregnancy is visualized, then pelvic pain and intraperitoneal fluid could be due to a ruptured ovarian cyst (eg, corpus luteum cyst, theca lutein cyst) or heterotopic pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link&amp;anchor=H23#H23\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\", section on 'Heterotopic pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ovarian torsion &mdash; Lower abdominal pain and an adnexal mass are the most common findings associated with ovarian torsion. Nausea and vomiting frequently accompany torsion, but are less common with cyst rupture. Imaging studies, particularly Doppler velocimetry, can help distinguish the two disorders, but the presence of a cystic or solid adnexal mass and free fluid in the posterior cul-de-sac are common with both entities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"       \"Ovarian and fallopian tube torsion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leiomyoma &mdash; Leiomyomas are associated with acute pain in the setting of carneous or red degeneration or torsion of a pedunculated tumor. Other findings that may be present include low grade fever, uterine tenderness on palpation, leukocytosis, and peritonitis. The discomfort resulting from degenerating leiomyomas is self-limited, lasting from days to a few weeks, and usually responds to nonsteroidal antiinflammatory drugs. Degenerating leiomyomas can be distinguished from ruptured ovarian cysts by imaging a leiomyoma originating in the uterus and by the lack of free intraperitoneal fluid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Pelvic pressure and pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pelvic inflammatory disease (PID) &mdash; Lower abdominal pain is the cardinal presenting symptom in women with PID. The onset of pain is more gradual than that with ruptured ovarian cysts, it is likely to occur during or shortly after menses rather than midcycle, and it is typically bilateral rather than unilateral. Free intraperitoneal fluid (pus) may or may not be observed on imaging. Abnormal uterine bleeding occurs in one-third of patients with PID and about 50 percent have leukocytosis or fever. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute endometritis &mdash; Acute endometritis occurs after an obstetrical delivery or, rarely, after an invasive uterine procedure. The diagnosis is largely based upon the presence of fever, gradual onset of uterine tenderness, foul uterine discharge, and leukocytosis in an at-risk setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"       \"Postpartum endometritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=see_link\">",
"       \"Endometritis unrelated to pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endometriosis &mdash; Common symptoms of endometriosis include pelvic pain (which is usually chronic and often more severe during menses or at ovulation), dysmenorrhea, deep dyspareunia, cyclical bowel or bladder symptoms, abnormal menstrual bleeding, and infertility. There are often no abnormal findings on physical examination; when findings are present, the most common is tenderness upon palpation of the posterior fornix. Ultrasound is mostly useful for diagnosing ovarian endometriomas; it lacks adequate resolution for visualizing adhesions and superficial",
"      <span class=\"nowrap\">",
"       peritoneal/ovarian",
"      </span>",
"      implants, which are more common than endometriomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uterine anomaly &mdash; Adolescents with obstructive uterine anomalies may present with primary amenorrhea, cyclic or chronic abdominopelvic pain, or a pelvic mass from hematometra. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link\">",
"       \"Congenital cervical anomalies and benign cervical lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ovarian hyperstimulation syndrome &mdash; Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of ovulation induction therapy and may be accompanied by or mistaken for cyst rupture. Severe ovarian hyperstimulation syndrome is characterized by large ovarian cysts, ascites, and, in some patients, pleural",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pericardial effusion, electrolyte imbalance (hyponatremia, hyperkalemia), hypovolemia, and hypovolemic shock. Marked hemoconcentration, increased blood viscosity, and thromboembolic phenomena including disseminated intravascular coagulation occur in the most severe cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35479?source=see_link\">",
"       \"Classification and treatment of ovarian hyperstimulation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sickle cell disease &mdash; Acute episodes of abdominal pain are a common manifestation of vasoocclusive events in women with sickle cell disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Acute painful episodes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hemoperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common gynecologic causes of hemoperitoneum are ruptured ovarian cyst and ectopic pregnancy. Hemoperitoneum may also be related to a hepatic, splenic, vascular, or coagulopathic etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/12\">",
"     12",
"    </a>",
"    ]. It is often due to blunt or penetrating traumatic injury to a visceral organ (especially the liver or spleen) or blood vessel, but may be spontaneous. Aneurysms (aorta, iliac or splenic artery), pseudoaneurysms, and veins may rupture and cause hemoperitoneum. Tumor-associated hemorrhage most often occurs in hepatocellular carcinoma, hepatic adenoma, metastatic disease to the liver, or vascular metastatic disease. Intraabdominal bleeding can also be caused by a perforated gastric ulcer or spontaneous splenic rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Peritoneal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myriad conditions are associated with visualization of small amounts of peritoneal fluid on ultrasound on CT examination. The most common causes of moderate to severe ascites are cirrhosis, cancer, congestive heart failure, and tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Uncomplicated cyst rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyst rupture is uncomplicated in the absence of hypotension, tachycardia, fever, signs of an acute abdomen, leukocytosis, or sonographic evidence of an enlarging hemoperitoneum or findings suggestive of malignancy.",
"   </p>",
"   <p>",
"    Women with uncomplicated cyst rupture can be managed as outpatients. Oral analgesia is given as needed. Nonhemorrhagic cyst fluid is usually resorbed within 24 hours and symptoms typically resolve within a few days. Follicular and corpus luteum cysts account for most of these cases.",
"   </p>",
"   <p>",
"    Surgical intervention may be indicated for diagnosis and treatment of ovarian cysts that are large or persistent, and those with findings suspicious for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complicated cyst rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have significant hemoperitoneum, we suggest hospitalization with fluid replacement, frequent vital signs, serial hematocrit levels, and repeated imaging to monitor bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/13\">",
"     13",
"    </a>",
"    ]. After bleeding has stopped, hemoperitoneum may take several weeks to resolve. Surgery is performed to control hemorrhage if the patient's clinical condition is unstable or deteriorating. We prefer to insert trocars under direct vision (open laparoscopy), particularly when there is abdominal distention. A large volume",
"    <span class=\"nowrap\">",
"     suction/irrigation",
"    </span>",
"    system and other appropriate operative laparoscopy tools should be available. Using a 10 mm cannula, large volumes of intraperitoneal blood and clot can be removed by alternating suction and irrigation. Laparotomy is a reasonable alternative if a surgeon with experience in operative laparoscopy is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After controlling hemorrhage, a frozen section diagnosis of the ovarian neoplasm is obtained. In a premenopausal woman with a benign ovarian cyst (physiologic or nonphysiologic), preservation of ovarian tissue via cystectomy is generally preferable to complete oophorectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link\">",
"     \"Oophorectomy and ovarian cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rupture of a dermoid cyst with spillage of sebaceous material into the abdominal cavity is uncommon. Shock and hemorrhage are the immediate sequelae of rupture; a marked granulomatous reaction (chemical peritonitis) may subsequently develop and lead to formation of dense adhesions and chronic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9863/abstract/15\">",
"     15",
"    </a>",
"    ]. For these reasons, we suggest emergency surgery if a ruptured dermoid cyst is suspected. Surgical intervention includes suction of spilled ovarian cyst contents, irrigation and suction to eliminate any residual sebaceous material, and cystectomy.",
"   </p>",
"   <p>",
"    Management of endometriomas and ovarian torsion is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"     \"Diagnosis and management of ovarian endometriomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"     \"Ovarian and fallopian tube torsion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consultation with a gynecologic oncologist is recommended if ovarian malignancy is suspected. Evaluation and treatment of women with suspected ovarian cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2219247\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no known methods to prevent rupture of an existing ovarian cyst, with the exception of surgical drainage or removal or the cyst. Hormonal suppression of ovulation may prevent cyst formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link&amp;anchor=H535724#H535724\">",
"     \"Management of an adnexal mass\", section on 'Premenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"       \"Patient information: Ovarian cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=see_link\">",
"       \"Patient information: Ovarian cysts (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rupture of an ovarian cyst is characterized by the sudden onset of unilateral, lower abdominal pain. The onset of pain is often during strenuous physical activities, such as exercise or sexual intercourse. Light vaginal bleeding may also occur due to a drop in ovarian hormone levels. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major goals in the evaluation of women with suspected rupture of an ovarian cyst are to exclude ruptured ectopic pregnancy, which has a similar clinical presentation, and to determine whether the patient can be safely managed expectantly or whether surgical intervention is needed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differential diagnosis includes mittelschmerz, ectopic pregnancy, ovarian torsion, degenerating leiomyoma, pelvic inflammatory disease, acute endometritis, and nongynecological disorders. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cyst rupture is uncomplicated in the absence of hypotension, tachycardia, fever, signs of an acute abdomen, leukocytosis, or sonographic evidence of an enlarging hemoperitoneum or malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women with uncomplicated cyst rupture, we suggest expectant management rather than surgical intervention (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). Later surgical intervention may be indicated for diagnosis and treatment of ovarian cysts that are large or persistent, and those with findings suspicious for malignancy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Uncomplicated cyst rupture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emergency surgery is performed to control ongoing significant hemorrhage. After controlling hemorrhage, a frozen section diagnosis of the ovarian neoplasm is obtained. In a premenopausal woman with a benign ovarian cyst, we suggest preservation of ovarian tissue via cystectomy rather than complete oophorectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Consultation with a gynecologic oncologist is recommended if ovarian malignancy is suspected. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complicated cyst rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest emergency surgical intervention for treatment of a ruptured dermoid cyst (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Spillage of sebaceous material can be accompanied by severe hemorrhage and chemical peritonitis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complicated cyst rupture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/1\">",
"      Dafopoulos K, Galazios G, Georgadakis G, et al. Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency. Gynecol Obstet Invest 2003; 55:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/2\">",
"      M&uuml;ller CH, Zimmermann K, Bettex HJ, et al. Near-fatal intra-abdominal bleeding from a ruptured follicle during thrombolytic therapy. Lancet 1996; 347:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/3\">",
"      Somers MP, Spears M, Maynard AS, Syverud SA. Ruptured heterotopic pregnancy presenting with relative bradycardia in a woman not receiving reproductive assistance. Ann Emerg Med 2004; 43:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/4\">",
"      Adams SL, Greene JS. Absence of a tachycardic response to intraperitoneal hemorrhage. J Emerg Med 1986; 4:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/5\">",
"      Jansen RP. Relative bradycardia: a sign of acute intraperitoneal bleeding. Aust N Z J Obstet Gynaecol 1978; 18:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/6\">",
"      Gupta N, Dadhwal V, Deka D, et al. Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities. J Obstet Gynaecol Res 2007; 33:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/7\">",
"      Peters WA 3rd, Thiagarajah S, Thornton WN Jr. Ovarian hemorrhage in patients receiving anticoagulant therapy. J Reprod Med 1979; 22:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/8\">",
"      Brooks RA. A quantitative theory of the Hounsfield unit and its application to dual energy scanning. J Comput Assist Tomogr 1977; 1:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/9\">",
"      Poletti PA, Kinkel K, Vermeulen B, et al. Blunt abdominal trauma: should US be used to detect both free fluid and organ injuries? Radiology 2003; 227:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/10\">",
"      Paajanen H, Lahti P, Nordback I. Sensitivity of transabdominal ultrasonography in detection of intraperitoneal fluid in humans. Eur Radiol 1999; 9:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/11\">",
"      Uharcek P, Mlyncek M, Ravinger J. Elevation of serum CA 125 and D-dimer levels associated with rupture of ovarian endometrioma. Int J Biol Markers 2007; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/12\">",
"      Lucey BC, Varghese JC, Anderson SW, Soto JA. Spontaneous hemoperitoneum: a bloody mess. Emerg Radiol 2007; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/13\">",
"      Barnes, AD. Nonsurgical management of a large hemoperitoneum from a ruptured corpus luteum: A 15-year study. The Female Patient 2005; 30:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/14\">",
"      Teng SW, Tseng JY, Chang CK, et al. Comparison of laparoscopy and laparotomy in managing hemodynamically stable patients with ruptured corpus luteum with hemoperitoneum. J Am Assoc Gynecol Laparosc 2003; 10:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9863/abstract/15\">",
"      Koshiba H. Severe chemical peritonitis caused by spontaneous rupture of an ovarian mature cystic teratoma: a case report. J Reprod Med 2007; 52:965.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3298 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9863=[""].join("\n");
var outline_f9_40_9863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory and imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hemoperitoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Peritoneal fluid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Uncomplicated cyst rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complicated cyst rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2219247\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3298\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3298|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/3/36913\" title=\"diagnostic image 1\">",
"      Ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/63/2034\" title=\"diagnostic image 2\">",
"      CT rupt corpus luteum cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3298|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/48/13069\" title=\"table 1\">",
"      Causes of an elevated CA 125",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35479?source=related_link\">",
"      Classification and treatment of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=related_link\">",
"      Endometritis unrelated to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40323?source=related_link\">",
"      History and physical examination in adults with abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=related_link\">",
"      Management of an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/20/2371?source=related_link\">",
"      Patient information: Ovarian cysts (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_40_9864="Intraoperative parathyroid hormone monitoring";
var content_f9_40_9864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraoperative parathyroid hormone monitoring",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9864/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9864/contributors\">",
"     Carmen C Solorzano, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9864/contributors\">",
"     Denise M Carneiro-Pla, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9864/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9864/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9864/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/40/9864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H32846697\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of abnormal parathyroid glands is the only curative treatment for primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/1\">",
"     1",
"    </a>",
"    ]. Monitoring parathyroid hormone (PTH) levels during surgery for sporadic primary hyperparathyroidism provides assurance that all hyperfunctioning parathyroid tissue has been adequately excised and the surgical procedure can be concluded.",
"   </p>",
"   <p>",
"    Compared with the traditional approach of a bilateral neck exploration to exclude multiglandular disease, intraoperative PTH monitoring allows a more focused, less invasive approach to parathyroid exploration without requiring direct visualization of every gland. A bilateral neck exploration requires visualization of all parathyroid glands and excision of enlarged gland(s), with preservation of normally functioning ones. The operative success rate of bilateral neck exploration varies with the experience of the surgeon. The success rate is more than 95 percent when performed by high volume, experienced surgeons, while operative failure occurs more frequently when surgery is performed by low volume surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/2\">",
"     2",
"    </a>",
"    ]. An inadequate operation is both costly and morbid, resulting in continuing symptoms of hyperparathyroidism, additional testing, reoperative surgery with increased risk of complications, and substantial expense [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/3-8\">",
"     3-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focused parathyroidectomy guided by intraoperative PTH monitoring minimizes neck dissection, prevents injury or excision of normally functioning glands, identifies multiple gland disease, and, with few exceptions, assures complete excision of all hypersecreting glands prior to leaving the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. In addition, intraoperative PTH measurements accurately predict postoperative calcium levels.",
"   </p>",
"   <p>",
"    The use of intraoperative PTH monitoring as an adjunct to parathyroid exploration in patients with sporadic primary hyperparathyroidism will be reviewed here. Parathyroid exploration, the role of preoperative localization, and the medical management of hyperparathyroidism are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18706042\">",
"    <span class=\"h1\">",
"     PARATHYROID HORMONE ASSAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative PTH monitoring takes advantage of the short half-life (three to five minutes) of PTH and utilizes a rapid immunochemiluminescence assay technique that allows measurements while the patient is still in the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The assay can be completed with a turnaround time of 8 to 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/16\">",
"     16",
"    </a>",
"    ]. Intraoperative rapid PTH assays measure the circulating amount of hormone at the time and from the location where the sample is obtained. Accuracy of intraoperative PTH monitoring is dependent upon the surgeon's knowledge and familiarity with PTH dynamics.",
"   </p>",
"   <p>",
"    Ideally, the intraoperative PTH assay should be performed in close proximity to the operating room to avoid long turnaround times caused by sample transport. The surgeon should be aware of variations in commercially available intraoperative PTH assays, especially if the PTH normal range is used as part of the required intraoperative PTH monitoring criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link\">",
"     \"Parathyroid hormone assays and their clinical use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32846719\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE PROTOCOLS FOR BLOOD SAMPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of intraoperative PTH monitoring is dependent upon the protocol used for blood sample collection. For each sample 3 to 5 mL of whole blood is collected in an EDTA tube. It is important to avoid hemolysis during blood collection by filling the EDTA tube completely and avoiding any shaking of the sample [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgeons should consistently use a protocol for intraoperative PTH monitoring that is practical, specific, and reproducible under their local conditions. Differing protocols for sample collection have evolved since intraoperative PTH monitoring was introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/18\">",
"     18",
"    </a>",
"    ] and validated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20236374\">",
"    <span class=\"h1\">",
"     SITE OF PTH SAMPLE COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative blood draws may be obtained from an arterial line, a peripheral intravenous line, or a neck vein.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral venous or arterial access can be obtained with a small catheter attached to an extension and stopcock that allows repeated blood samples to be collected by the anesthesiologist at the times requested by the surgeon. This catheter may be kept open with saline infusion, or heparinized solution may be instilled and a cap applied. To prevent dilution the first 10 cc must be discarded from the line before the blood PTH sample is drawn [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Central access can be obtained directly by the surgeon from the internal jugular vein or the anterior jugular vein using a syringe. If drawn ipsilateral to a single adenoma, internal jugular PTH levels can be higher than those from a peripheral source and can take longer to fall into the normal range, possibly leading to misinterpreted results [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20236381\">",
"    <span class=\"h1\">",
"     PROTOCOLS FOR PTH SAMPLE COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many protocols for intraoperative PTH monitoring have been studied as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef64080 \" href=\"UTD.htm?7/9/7326\">",
"     table 1",
"    </a>",
"    ). Here we present two protocols that consistently produce good results:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152206108\">",
"    <span class=\"h2\">",
"     The \"&gt;50 percent drop\" criterion and protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;One widely accepted and well validated method requires at least four intraoperative PTH samples as well as an assay type with a total sample turnaround time of less than 15 minutes (",
"    <a class=\"graphic graphic_table graphicRef64080 \" href=\"UTD.htm?7/9/7326\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/18,23-26\">",
"     18,23-26",
"    </a>",
"    ]. This protocol utilizes a drop in PTH values of &gt;50 percent from the",
"    <strong>",
"     highest level",
"    </strong>",
"    (either pre-incision or pre-excision) as the criterion to conclude surgery.",
"   </p>",
"   <p>",
"    The \"&gt;50 percent PTH drop\" criterion can also predict postoperative calcium levels for at least six months (",
"    <a class=\"graphic graphic_table graphicRef75868 \" href=\"UTD.htm?6/34/6699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/27\">",
"     27",
"    </a>",
"    ]. As an example, a retrospective study of 341 patients showed the \"&gt;50 percent PTH drop\" criterion correctly predicted postoperative calcium levels in 329 patients (96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pre-incision",
"      </strong>",
"      &ndash; The first blood sample is collected in the operating room from a peripheral intravenous or arterial line before the skin is incised [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pre-excision (time zero)",
"      </strong>",
"      &ndash; The second blood sample is collected just before the blood supply to the suspicious gland is clamped. The PTH level at time zero may drop significantly from the pre-incision level because the abnormal parathyroid gland's main blood supply is potentially disrupted at the beginning of the dissection as shown in the figure (",
"      <a class=\"graphic graphic_figure graphicRef62746 \" href=\"UTD.htm?3/59/4031\">",
"       figure 1",
"      </a>",
"      ). Thus, pre-incision and pre-excision samples are necessary to accurately calculate the &gt;50 percent drop.",
"      <br/>",
"      <br/>",
"      Timing is important for this sample because a PTH sample collected too early during parathyroid gland dissection, or collected after early disruption of the blood supply, could potentially miss the peak of PTH level and lead to a false negative result (",
"      <a class=\"graphic graphic_figure graphicRef62746 \" href=\"UTD.htm?3/59/4031\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H152206154\">",
"       'False negative PTH results'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Five minutes",
"      </strong>",
"      &ndash; The third blood sample is collected five minutes after excision of the suspected abnormal gland.",
"     </li>",
"     <li>",
"      <strong>",
"       Ten minutes",
"      </strong>",
"      &ndash; The fourth blood sample is collected ten minutes after excision of the suspected abnormal gland. The PTH data are then plotted in a curve and examined.",
"     </li>",
"     <li>",
"      <strong>",
"       Complete excision criteria",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      When peripheral PTH values drop &gt;50 percent from the",
"      <strong>",
"       highest level",
"      </strong>",
"      (either pre-incision or pre-excision) by ten minutes after excision of all abnormal parathyroid glands, the procedure can thus be stopped without further neck exploration or visualization of the remaining normally secreting parathyroid glands.",
"      <br/>",
"      <br/>",
"      If the PTH",
"      <strong>",
"      </strong>",
"      value does not drop appropriately by ten minutes after gland excision, the surgeon can repeat the PTH level at 20 minutes. In most of these patients, the intraoperative PTH monitoring criterion is met with this additional measurement [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/24,28\">",
"       24,28",
"      </a>",
"      ]. If the criterion is not met after twenty minutes, further dissection should continue until additional glands are removed and the criterion is fulfilled. This protocol for blood sampling is repeated for each additional excised gland.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152206275\">",
"    <span class=\"h2\">",
"     The \"Normal Range\" criterion and protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another widely used method for PTH monitoring, which was adapted from the \"&gt;50 percent PTH drop\" protocol, requires at least two intraoperative samples and allows use of assay types that have &gt;15 minutes total sample turnaround time (",
"    <a class=\"graphic graphic_table graphicRef64080 \" href=\"UTD.htm?7/9/7326\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/19,29-32\">",
"     19,29-32",
"    </a>",
"    ]. This protocol utilizes",
"    <strong>",
"     both",
"    </strong>",
"    a drop in PTH values of &gt;50 percent from the highest level",
"    <strong>",
"     and",
"    </strong>",
"    a return of the PTH to the normal range as the criteria to conclude surgery. When both of these criteria are used, postoperative normal or low calcium levels are predicted with excellent accuracy. As an example, in a series of 1882 patients who underwent parathyroidectomy for primary hyperparathyroidism, the &ldquo;normal range&rdquo; criterion correctly predicted normocalcemia in 1830 patients (97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pre-incision",
"      </strong>",
"      &ndash; The first blood sample is collected in the operating room from a peripheral intravenous or arterial line, or centrally, before the skin is incised.",
"     </li>",
"     <li>",
"      <strong>",
"       Ten minutes",
"      </strong>",
"      &ndash; The second blood sample is collected from the same site ten to twenty minutes after excision of the suspected adenoma or 10 minutes after subtotal resection of multiglandular parathyroid disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Complete excision criteria",
"      </strong>",
"      &ndash; When the PTH value drops both by &gt;50 percent from the baseline level and also into the normal range, the surgery is concluded [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/19,33\">",
"       19,33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If the PTH level does not drop by both criteria, a third level is drawn and its results direct further management. If the third level drops into the normal range, the operation is concluded. Continued PTH elevation prompts further parathyroid exploration with removal of additional enlarged glands until both functional criteria are fulfilled.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67515644\">",
"    <span class=\"h2\">",
"     Stricter criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stricter criteria for intraoperative success include a larger PTH level percent drop (&gt;65 to 70 percent) or a PTH decrease at five minutes after gland excision (",
"    <a class=\"graphic graphic_table graphicRef64080 \" href=\"UTD.htm?7/9/7326\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/27,30,34\">",
"     27,30,34",
"    </a>",
"    ]. The use of such criteria may decrease the number of operative failures, but may also increase the incidence of false negative results, leading to additional unnecessary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, in a series of 1882 patients who underwent parathyroidectomy for primary hyperparathyroidism, if the criterion of a 50 percent drop at only five minutes after gland excision had been used, the number of patients with false negative results would have increased from 66 to 272 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H736927\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF PTH DYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several intraoperative criteria have been used to interpret PTH levels during surgery and predict normal or low postoperative calcium levels (",
"    <a class=\"graphic graphic_table graphicRef64080 \" href=\"UTD.htm?7/9/7326\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/6,19,27,29-31,35-46\">",
"     6,19,27,29-31,35-46",
"    </a>",
"    ]. Guidelines for interpretation of intraoperative PTH levels are provided here:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H843191053\">",
"    <span class=\"h2\">",
"     True positive PTH results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A true positive PTH result occurs when intraoperative PTH drops adequately after gland excision and correctly predicts operative success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H843191060\">",
"    <span class=\"h2\">",
"     True negative PTH results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A true negative result leads the surgeon appropriately to continue neck exploration for additional gland excision. If another gland is not found, the lack of intraoperative PTH drop will predict operative failure due to insufficient resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H843191112\">",
"    <span class=\"h2\">",
"     False positive PTH results",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive results can occur but are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. False positive results are defined as an apparently appropriate decrease in PTH, followed by persistent hyperparathyroidism postoperatively. This scenario should raise suspicion for a multiple endocrine neoplasia (MEN) syndrome, parathyroid carcinoma, or other familial causes of hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152206154\">",
"    <span class=\"h2\">",
"     False negative PTH results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A false negative PTH result leads to continuation of the surgical exploration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anesthesia time even though the degree of parathyroid resection has already been adequate. When false negative results are suspected, a down-sloping post-resection PTH curve can provide assurance that surgery will be curative.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      False negative results can occur when the baseline PTH level is drawn from an internal jugular vein ipsilateral to (ie, draining) a single adenoma. In this circumstance it can take longer for the PTH level to drop adequately after adenoma resection.",
"     </li>",
"     <li>",
"      In the \"&gt;50 percent PTH drop\" criterion, which uses the sole criterion of a &gt;50 percent drop in the PTH level, a missed PTH peak can lead to a false negative result if the PTH level was in fact much higher either after (by adenoma manipulation during dissection) or before (by early vascular disruption) the pre-excision level was drawn (",
"      <a class=\"graphic graphic_figure graphicRef62746 \" href=\"UTD.htm?3/59/4031\">",
"       figure 1",
"      </a>",
"      ). That is why examination of the entire curve can be helpful. (See",
"      <a class=\"local\" href=\"#H152206108\">",
"       'The \"&gt;50 percent drop\" criterion and protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the \"Normal Range\" criterion, which adds the second criterion of a drop into the normal range, false negative results can prolong anesthesia time. In most cases the incision has already been closed; when the third intraoperative PTH level drops adequately, the surgery is concluded. (See",
"      <a class=\"local\" href=\"#H152206275\">",
"       'The \"Normal Range\" criterion and protocol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343302506\">",
"    <span class=\"h1\">",
"     PTH LEVELS FOR SPECIAL ANATOMIC CIRCUMSTANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative PTH levels can help with the identification of multiple gland disease, missing glands, and the lateralization of hyperfunctioning glands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32846726\">",
"    <span class=\"h2\">",
"     Multiple gland disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of multiglandular disease in patients with sporadic hyperparathyroidism ranges from 5 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Use of the \"&gt;50 percent PTH drop\" criterion alone is associated with resection of multiple glands in 3 to 10 percent of patients and operative success rates of 97 to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/34-36,49-52\">",
"     34-36,49-52",
"    </a>",
"    ]. The rates of multiple gland resection are higher when both the \"&gt;50 percent PTH drop\" criterion and the requirement that PTH return to the normal range are used or when bilateral neck exploration is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/13,29,41,53-56\">",
"     13,29,41,53-56",
"    </a>",
"    ]. This appears to be due to surgical resection of additional \"enlarged\" glands that are assumed to be hyperfunctioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/30,39-41,43,46,57,58\">",
"     30,39-41,43,46,57,58",
"    </a>",
"    ]. However, gland size or weight does not always correlate with parathyroid function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/59\">",
"     59",
"    </a>",
"    ]. Although randomized trials have demonstrated that operative success rates are not improved by the excision of additional \"enlarged\" glands, debate continues about whether it is parathyroid gland",
"    <span class=\"nowrap\">",
"     size/weight",
"    </span>",
"    or function that best defines an abnormality requiring resection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/52,60\">",
"     52,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9783594\">",
"    <span class=\"h2\">",
"     Missing glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;For localization of a missing gland, bilateral jugular venous sampling for PTH levels can be performed at the time of exploration and are especially helpful during difficult exploration. A unilateral elevation is suspicious for a missing hyperfunctioning gland on that side.",
"    <strong>",
"    </strong>",
"    Bilateral internal jugular PTH levels that are similar may be suggestive of hyperfunctioning parathyroid disease outside the neck (eg, in the mediastinum). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H1352796#H1352796\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Missing parathyroid glands'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20236638\">",
"    <span class=\"h2\">",
"     Lateralization of hyperfunctioning glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative or preoperative jugular venous PTH sampling can be performed to lateralize the side of the neck harboring the most hyperfunctioning parathyroid gland(s) for patients with negative preoperative localization studies, thus avoiding bilateral neck exploration.",
"   </p>",
"   <p>",
"    For intraoperative differential jugular venous sampling, samples from both internal jugular veins, preferably guided by ultrasound, are taken before skin incision for rapid PTH measurement (",
"    <a class=\"graphic graphic_figure graphicRef50992 \" href=\"UTD.htm?34/42/35494\">",
"     figure 2",
"    </a>",
"    ). This guides the surgeon to the side of the neck with the highest PTH level (10 percent higher than the opposite side), leading to a successful unilateral neck exploration in 70 to 80 percent of patients when used in conjunction with intraoperative PTH monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound guided differential jugular venous sampling has also been successfully performed in the outpatient setting for preoperative localization of parathyroid glands in patients with equivocal ultrasound findings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32846756\">",
"    <span class=\"h1\">",
"     PTH LEVELS FOR PARATHYROID TISSUE IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration of parathyroid tissue for PTH measurement can differentiate parathyroid tissue from other tissues with a specificity of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. A 25-gauge needle attached to a syringe is used to collect the tissue sample. The content aspirated in the needle is diluted with 1 mL of saline solution and centrifuged, and the supernatant is used for PTH measurement with the rapid PTH assay. This technique provides quick tissue identification without frozen section, and it can be helpful when gland identification is difficult, as in the case of an intrathyroidal parathyroid, an indeterminate exophytic thyroid nodule, or enlarged lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H1850183#H1850183\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'First enlarged parathyroid gland'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H738252\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many endocrine surgeons use intraoperative PTH monitoring rather than bilateral neck exploration to guide parathyroidectomy for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with sporadic primary hyperparathyroidism, parathyroid exploration guided by intraoperative PTH monitoring is successful in &gt;97 percent of cases, with less extensive surgical dissection, shorter operative times, and smaller incisions than bilateral neck exploration [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/9-12,19,33\">",
"       9-12,19,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If outpatient surgery can be performed, intraoperative PTH monitoring leads to a 50 percent decrease in hospital costs and patient charges when compared with bilateral neck exploration despite an increase in laboratory costs [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/57,66\">",
"       57,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with equivocal or negative preoperative localization studies [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/67\">",
"       67",
"      </a>",
"      ] and those requiring reoperation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9864/abstract/6,25,68\">",
"       6,25,68",
"      </a>",
"      ], intraoperative PTH monitoring improves the operative success rate, allowing successful unilateral neck exploration in more than 80 percent of such patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32846777\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitoring changes in parathyroid hormone (PTH) levels during surgery for sporadic primary hyperparathyroidism provides a useful tool to indicate when all hyperfunctioning parathyroid tissue has been adequately excised, and accurately predicts postoperative results.",
"     </li>",
"     <li>",
"      Intraoperative PTH monitoring allows a more focused, less invasive approach to parathyroidectomy than a bilateral neck exploration. (See",
"      <a class=\"local\" href=\"#H32846697\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraoperative PTH monitoring takes advantage of the short plasma half-life (three to five minutes) of PTH by using a rapid assay technique that allows measurements while the patient is still in the operating room. (See",
"      <a class=\"local\" href=\"#H18706042\">",
"       'Parathyroid hormone assay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraoperative blood samples are usually obtained from a peripheral intravenous or arterial line. PTH levels can be obtained from the internal jugular vein but may take longer to fall into the normal range, which can lead to false negative results. (See",
"      <a class=\"local\" href=\"#H20236374\">",
"       'Site of PTH sample collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTH levels are measured at specific time points during the procedure. Each center should consistently use an algorithm that is practical and reproducible given the resources available. (See",
"      <a class=\"local\" href=\"#H20236381\">",
"       'Protocols for PTH sample collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that surgeons consistently use a protocol for intraoperative PTH monitoring that is practical, specific, and reproducible under their local conditions, using either the &gt;50 percent PTH drop from baseline criterion alone or the additional normal range criterion as intraoperative confirmation of operative success rather than stricter criteria (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The use of stricter criteria may decrease the number of operative failures, but also may lead to additional unnecessary surgery. (See",
"      <a class=\"local\" href=\"#H20236381\">",
"       'Protocols for PTH sample collection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/1\">",
"      Fraker DL, Harsono H, Lewis R. Minimally invasive parathyroidectomy: benefits and requirements of localization, diagnosis, and intraoperative PTH monitoring. long-term results. World J Surg 2009; 33:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/2\">",
"      Chen H, Wang TS, Yen TW, et al. Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume. Ann Surg 2010; 252:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/3\">",
"      Kaplan EL, Yashiro T, Salti G. Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease. Ann Surg 1992; 215:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/4\">",
"      Low RA, Katz AD. Parathyroidectomy via bilateral cervical exploration: a retrospective review of 866 cases. Head Neck 1998; 20:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/5\">",
"      Ud&eacute;n P, Chan A, Duh QY, et al. Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery. World J Surg 1992; 16:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/6\">",
"      Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg 1999; 229:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/7\">",
"      Malmaeus J, Granberg PO, Halvorsen J, et al. Parathyroid surgery in Scandinavia. Acta Chir Scand 1988; 154:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/8\">",
"      Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery 1994; 116:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/9\">",
"      Irvin GL 3rd, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg 1991; 162:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/10\">",
"      Chapuis Y, Icard P, Fulla Y, et al. [Excision under local anesthesia of parathyroid adenomas. Criteria of selection and control of effectiveness. 35 cases]. Presse Med 1991; 20:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/11\">",
"      Bergenfelz A, Nord&eacute;n NE, Ahr&eacute;n B. Intraoperative fall in plasma levels of intact parathyroid hormone after removal of one enlarged parathyroid gland in hyperparathyroid patients. Eur J Surg 1991; 157:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/12\">",
"      Greene AB, Butler RS, McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg 2009; 209:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/13\">",
"      Carneiro DM, Irvin GL 3rd. Late parathyroid function after successful parathyroidectomy guided by intraoperative hormone assay (QPTH) compared with the standard bilateral neck exploration. Surgery 2000; 128:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/14\">",
"      Sokoll LJ, Drew H, Udelsman R. Intraoperative parathyroid hormone analysis: A study of 200 consecutive cases. Clin Chem 2000; 46:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/15\">",
"      Delbridge LW, Dolan SJ, Hop TT, et al. Minimally invasive parathyroidectomy: 50 consecutive cases. Med J Aust 2000; 172:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/16\">",
"      Carneiro-Pla D. Contemporary and practical uses of intraoperative parathyroid hormone monitoring. Endocr Pract 2011; 17 Suppl 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/17\">",
"      Lippi G, Blanckaert N, Bonini P, et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med 2008; 46:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/18\">",
"      Irvin GL 3rd, Deriso GT 3rd. A new, practical intraoperative parathyroid hormone assay. Am J Surg 1994; 168:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/19\">",
"      Carty SE, Worsey J, Virji MA, et al. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery 1997; 122:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/20\">",
"      Broome JT, Schrager JJ, Bilheimer D, et al. Central venous sampling for intraoperative parathyroid hormone monitoring: are peripheral guidelines applicable? Am Surg 2007; 73:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/21\">",
"      Beyer TD, Chen E, Ata A, et al. A prospective evaluation of the effect of sample collection site on intraoperative parathormone monitoring during parathyroidectomy. Surgery 2008; 144:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/22\">",
"      Woodrum DT, Saunders BD, England BG, et al. The influence of sample site on intraoperative PTH monitoring during parathyroidectomy. Surgery 2004; 136:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/23\">",
"      Irvin GL 3rd, Prudhomme DL, Deriso GT, et al. A new approach to parathyroidectomy. Ann Surg 1994; 219:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/24\">",
"      Carneiro DM, Solorzano CC, Nader MC, et al. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 2003; 134:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/25\">",
"      Irvin GL 3rd, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg 2004; 28:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/26\">",
"      Sol&oacute;rzano CC, Carneiro-Pla DM, Lew JI, et al. Intra-operative parathyroid hormone monitoring in patients with parathyroid cancer. Ann Surg Oncol 2007; 14:3216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/27\">",
"      Irvin GL 3rd, Dembrow VD, Prudhomme DL. Clinical usefulness of an intraoperative \"quick parathyroid hormone\" assay. Surgery 1993; 114:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/28\">",
"      Di Stasio E, Carrozza C, Pio Lombardi C, et al. Parathyroidectomy monitored by intra-operative PTH: the relevance of the 20 min end-point. Clin Biochem 2007; 40:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/29\">",
"      Burkey SH, Van Heerden JA, Farley DR, et al. Will directed parathyroidectomy utilizing the gamma probe or intraoperative parathyroid hormone assay replace bilateral cervical exploration as the preferred operation for primary hyperparathyroidism? World J Surg 2002; 26:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/30\">",
"      Chiu B, Sturgeon C, Angelos P. Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients. Arch Surg 2006; 141:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/31\">",
"      Yang GP, Levine S, Weigel RJ. A spike in parathyroid hormone during neck exploration may cause a false-negative intraoperative assay result. Arch Surg 2001; 136:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/32\">",
"      Richards ML, Thompson GB, Farley DR, Grant CS. An optimal algorithm for intraoperative parathyroid hormone monitoring. Arch Surg 2011; 146:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/33\">",
"      Carty SE, Roberts MM, Virji MA, et al. Elevated serum parathormone level after \"concise parathyroidectomy\" for primary sporadic hyperparathyroidism. Surgery 2002; 132:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/34\">",
"      Garner SC, Leight GS Jr. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery 1999; 126:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/35\">",
"      Johnson LR, Doherty G, Lairmore T, et al. Evaluation of the performance and clinical impact of a rapid intraoperative parathyroid hormone assay in conjunction with preoperative imaging and concise parathyroidectomy. Clin Chem 2001; 47:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/36\">",
"      Inabnet WB 3rd, Dakin GF, Haber RS, et al. Targeted parathyroidectomy in the era of intraoperative parathormone monitoring. World J Surg 2002; 26:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/37\">",
"      Agarwal G, Barakate MS, Robinson B, et al. Intraoperative quick parathyroid hormone versus same-day parathyroid hormone testing for minimally invasive parathyroidectomy: a cost-effectiveness study. Surgery 2001; 130:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/38\">",
"      Gauger PG, Agarwal G, England BG, et al. Intraoperative parathyroid hormone monitoring fails to detect double parathyroid adenomas: a 2-institution experience. Surgery 2001; 130:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/39\">",
"      Miura D, Wada N, Arici C, et al. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy? World J Surg 2002; 26:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/40\">",
"      Perrier ND, Ituarte PH, Morita E, et al. Parathyroid surgery: separating promise from reality. J Clin Endocrinol Metab 2002; 87:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/41\">",
"      Gordon LL, Snyder WH 3rd, Wians F Jr, et al. The validity of quick intraoperative parathyroid hormone assay: an evaluation in seventy-two patients based on gross morphologic criteria. Surgery 1999; 126:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/42\">",
"      Libutti SK, Alexander HR, Bartlett DL, et al. Kinetic analysis of the rapid intraoperative parathyroid hormone assay in patients during operation for hyperparathyroidism. Surgery 1999; 126:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/43\">",
"      Weber CJ, Ritchie JC. Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration. Surgery 1999; 126:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/44\">",
"      Lupoli GA, Fonderico F, Panico A, et al. Stricter criteria increase the validity of a quick intraoperative parathyroid hormone assay in primary hyperparathyroidism. Med Sci Monit 2009; 15:CR111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/45\">",
"      Lombardi CP, Raffaelli M, Traini E, et al. Intraoperative PTH monitoring during parathyroidectomy: the need for stricter criteria to detect multiglandular disease. Langenbecks Arch Surg 2008; 393:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/46\">",
"      Riss P, Kaczirek K, Heinz G, et al. A \"defined baseline\" in PTH monitoring increases surgical success in patients with multiple gland disease. Surgery 2007; 142:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/47\">",
"      Gill MT, Dean M, Karr J, et al. Intraoperative parathyroid hormone assay: a necessary tool for multiglandular disease. Otolaryngol Head Neck Surg 2011; 144:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/48\">",
"      Lew JI, Solorzano CC, Montano RE, et al. Role of intraoperative parathormone monitoring during parathyroidectomy in patients with discordant localization studies. Surgery 2008; 144:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/49\">",
"      Miccoli P, Berti P, Materazzi G, et al. Results of video-assisted parathyroidectomy: single institution's six-year experience. World J Surg 2004; 28:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/50\">",
"      Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol 2002; 146:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/51\">",
"      Thanasoulis L, Bingener J, Sirinek K, Richards M. A successful application of the intraoperative parathyroid hormone assay in tertiary hyperparathyroidism. Am Surg 2007; 73:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/52\">",
"      Genc H, Morita E, Perrier ND, et al. Differing histologic findings after bilateral and focused parathyroidectomy. J Am Coll Surg 2003; 196:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/53\">",
"      Carneiro DM, Solorzano CC, Irvin GL 3rd. Recurrent disease after limited parathyroidectomy for sporadic primary hyperparathyroidism. J Am Coll Surg 2004; 199:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/54\">",
"      Carneiro-Pla DM, Solorzano CC, Lew JI, Irvin GL 3rd. Long-term outcome of patients with intraoperative parathyroid level remaining above the normal range during parathyroidectomy. Surgery 2008; 144:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/55\">",
"      Tezelman S, Shen W, Shaver JK, et al. Double parathyroid adenomas. Clinical and biochemical characteristics before and after parathyroidectomy. Ann Surg 1993; 218:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/56\">",
"      Proye CA, Carnaille B, Bizard JP, et al. Multiglandular disease in seemingly sporadic primary hyperparathyroidism revisited: where are we in the early 1990s? A plea against unilateral parathyroid exploration. Surgery 1992; 112:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/57\">",
"      De Pasquale L, Gobatti D, Ravini ML, et al. Intra-operative testing for parathyroid hormone: the Central Laboratory option. J Endocrinol Invest 2008; 31:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/58\">",
"      Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg 2008; 248:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/59\">",
"      Liechty RD, Teter A, Suba EJ. The tiny parathyroid adenoma. Surgery 1986; 100:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/60\">",
"      Miccoli P, Berti P, Materazzi G, et al. Endoscopic bilateral neck exploration versus quick intraoperative parathormone assay (qPTHa) during endoscopic parathyroidectomy: A prospective randomized trial. Surg Endosc 2008; 22:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/61\">",
"      Ito F, Sippel R, Lederman J, Chen H. The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg 2007; 245:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/62\">",
"      Carneiro-Pla D. Effectiveness of \"office\"-based, ultrasound-guided differential jugular venous sampling (DJVS) of parathormone in patients with primary hyperparathyroidism. Surgery 2009; 146:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/63\">",
"      Doppman JL, Krudy AG, Marx SJ, et al. Aspiration of enlarged parathyroid glands for parathyroid hormone assay. Radiology 1983; 148:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/64\">",
"      Hor&aacute;nyi J, Duffek L, Szl&aacute;vik R, et al. Intraoperative determination of PTH concentrations in fine needle tissue aspirates to identify parathyroid tissue during parathyroidectomy. World J Surg 2010; 34:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/65\">",
"      Okelo GB. Current management of rare parasitic diseases. East Afr Med J 1991; 68:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/66\">",
"      Chen H, Sokoll LJ, Udelsman R. Outpatient minimally invasive parathyroidectomy: a combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay. Surgery 1999; 126:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/67\">",
"      Thier M, Nordenstr&ouml;m E, Bergenfelz A, Westerdahl J. Surgery for patients with primary hyperparathyroidism and negative sestamibi scintigraphy--a feasibility study. Langenbecks Arch Surg 2009; 394:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9864/abstract/68\">",
"      Irvin GL 3rd, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg 2004; 239:704.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15031 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9864=[""].join("\n");
var outline_f9_40_9864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32846777\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32846697\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18706042\">",
"      PARATHYROID HORMONE ASSAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32846719\">",
"      INTRAOPERATIVE PROTOCOLS FOR BLOOD SAMPLING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20236374\">",
"      SITE OF PTH SAMPLE COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20236381\">",
"      PROTOCOLS FOR PTH SAMPLE COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152206108\">",
"      The \"&gt;50 percent drop\" criterion and protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152206275\">",
"      The \"Normal Range\" criterion and protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67515644\">",
"      Stricter criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H736927\">",
"      INTERPRETATION OF PTH DYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H843191053\">",
"      True positive PTH results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H843191060\">",
"      True negative PTH results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H843191112\">",
"      False positive PTH results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152206154\">",
"      False negative PTH results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H343302506\">",
"      PTH LEVELS FOR SPECIAL ANATOMIC CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32846726\">",
"      Multiple gland disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9783594\">",
"      Missing glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20236638\">",
"      Lateralization of hyperfunctioning glands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32846756\">",
"      PTH LEVELS FOR PARATHYROID TISSUE IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H738252\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32846777\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15031|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/59/4031\" title=\"figure 1\">",
"      Intraoperative PTH dynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/42/35494\" title=\"figure 2\">",
"      Jugular venous sampling of PTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/9/7326\" title=\"table 1\">",
"      Intraoperative PTH monitoring - Criteria used to guide surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/34/6699\" title=\"table 2\">",
"      Predicting the success of a parathyroidectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=related_link\">",
"      Parathyroid hormone assays and their clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_40_9865="Initial treatment of limited stage (I/II) follicular lymphoma";
var content_f9_40_9865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of limited stage (I/II) follicular lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9865/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9865/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9865/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9865/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9865/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9865/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/40/9865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H841817\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular lymphoma (FL, previously called follicle center lymphoma) is the second most common type of non-Hodgkin lymphoma (NHL). It is the most common of the indolent NHLs defined as those lymphomas in which survival of the untreated patient is measured in years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of FL depends upon the stage of disease at presentation as evaluated by the Ann Arbor Staging system (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). Patients with localized (stage I) disease are candidates for radiation therapy, which is curative in a percentage of patients. In contrast, the treatment of advanced (stage",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    disease is not curative and focuses largely on symptom control with chemoimmunotherapy with or without radiation therapy. The management of patients with stage II FL is more variable, with some clinicians offering treatment similar to that used for stage I disease, and others offering treatment similar to that used for advanced stage disease. (See",
"    <a class=\"local\" href=\"#H87719265\">",
"     'Bulky stage II FL'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial treatment of limited stage FL is discussed here. The initial treatment of advanced stage FL and the management of relapsed or refractory FL are presented separately, as are the epidemiology, clinical presentation, pathologic features, diagnosis, and pathobiology of follicular lymphoma. Of importance, the recommendations presented here pertain to patients with histologic grade I, II, or IIIa FL; patients with grade IIIb FL are treated as aggressive lymphomas (eg, diffuse large B cell lymphoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243868#H26243868\">",
"     \"Pathobiology of follicular lymphoma\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link\">",
"     \"Pathobiology of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRE-TREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with NHL must establish the precise histologic subtype, the extent and sites of disease, and the performance status of the patient. These investigations are important for determining the treatment strategy and for predicting outcome with the Follicular Lymphoma International Prognostic Index (FLIPI) or one of its variants. General approaches to the diagnostic work-up and staging of NHL are presented separately (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a diagnosis and pathologic grade of FL is confirmed, the pre-treatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. Of particular importance, information gathered from this evaluation is used to determine the patient's Follicular Lymphoma International Prognostic Index (FLIPI) (",
"    <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"     table 2",
"    </a>",
"    ) score, which determines whether the patient is at low, intermediate, or high risk for progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H75814042#H75814042\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Follicular lymphoma IPI (FLIPI)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to a history and physical examination, it is our practice to perform the following pre-treatment studies in patients with FL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), and hepatitis B. All patients with FL should be encouraged to undergo serologic testing for HIV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy is recommended prior to the initiation of therapy. If radioimmunotherapy is planned, a bilateral core biopsy is required. For patients electing initial observation, bone marrow evaluation may be postponed until therapy is required.",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis should be performed. While some clinicians routinely include the neck in the CT scan, we typically only include it if lymph nodes in the neck are palpable on physical examination. For patients with limited stage disease, we suggest obtaining a combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scan as a measure of disease activity. FL is considered a typically FDG-avid tumor such that involved areas should show activity on PET scan. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of cardiac ejection fraction (eg, echocardiogram, MUGA, cardiac MRI) should be performed if the planned chemotherapy regimen includes anthracyclines or anthracenediones.",
"     </li>",
"     <li>",
"      Performance status should be evaluated using either the Eastern Cooperative Oncology Group (ECOG) performance scale (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 3",
"      </a>",
"      ) or the Karnofsky performance scale (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Men and women with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures (eg, sperm banking). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although oncologic emergencies and severe disease-related complications are more common in the aggressive and highly aggressive NHLs, the physician must always be alert to their potential presence, and be prepared to deal with them urgently and effectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Oncologic emergencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19679373\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited stage disease is that which is limited to a single lymph node region (stage I), single extralymphatic organ or site (stage IE), or more than one lymph node or lymphatic structure on the same side of the diaphragm alone (stage II) or with involvement of a limited, contiguous extralymphatic organ or tissue (stage IIE) (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). Approximately 15 to 30 percent of patients with FL will present with clinical stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    disease, and less than 10 percent have pathologic stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been few prospective trials of therapy for limited stage FL and most of the data on this subgroup of patients come from retrospective analyses. Unlike in advanced stage disease, a small percentage of patients with early stage disease may have long-term disease-free survival suggesting cure. As such, most patients are offered initial therapy. Rarely, patients may have spontaneous complete remissions. Spontaneous partial remissions occur in approximately 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite evidence demonstrating the potential for cure, only a minority (27 percent) of patients with stage I disease treated in the United States receives radiation therapy (RT) as a single modality treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Instead, patients commonly receive initial treatment with immunochemotherapy (28 percent), immunochemotherapy plus RT (13 percent), or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (12 percent), or are observed until progression (17 percent). Observational studies suggest differences in progression-free survival rates with these different treatment strategies, but have not demonstrated a difference in survival.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy &mdash; RT results in 10-year overall survival rates of 60 to 80 percent; median survival is approximately 19 years [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/5\">",
"       5",
"      </a>",
"      ]. Some patients may be cured with RT alone. Short- and long-term toxicities associated with RT are dependent upon the site of disease, radiation field, and dose. Adjuvant chemotherapy does not appear to add additional benefit after local RT.",
"     </li>",
"     <li>",
"      Observation &mdash; Observation is a reasonable alternative to RT if significant morbidity is expected from RT based on the location of the tumor or if the patient chooses against RT. Patients who choose this approach are expected to progress sooner than those who select immediate therapy. By postponing treatment, the patient avoids potential toxicity; however, the expected increased size of the tumor at the time of progression may also limit treatment options at the time of progression. This approach may be most appropriate for the many stage II patients who are not ideal candidates for RT due to the location of their disease and expected toxicities.",
"     </li>",
"     <li>",
"      Chemoimmunotherapy &mdash; Some clinicians choose to treat patients with limited stage FL with chemoimmunotherapy or immunotherapy with or without RT, such as that used for patients with advanced stage FL. With this approach, 10-year overall survival and progression-free survival rates were 80 and 72 percent, in one case series [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/6\">",
"       6",
"      </a>",
"      ]. Short-term toxicities depend upon the regimen used, but usually include immunosuppression, infections, gastrointestinal distress, and infusion related reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For most patients with stage I or nonbulky stage II FL, we suggest initial treatment with radiation therapy rather than treatment with chemotherapy or an initial period of observation. This approach is consistent with that presented by the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/7\">",
"     7",
"    </a>",
"    ]. While the recommendations presented apply to most patients with FL, patients with certain tumor characteristics (eg, grade IIIb FL, bulky stage II FL) require special modifications to this approach. These are described in more detail below. In addition, the treatment of primary cutaneous follicle center lymphoma, which, by definition, is localized to the skin, is discussed separately. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Special situations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"     \"Primary cutaneous follicle center lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation (RT) is the preferred therapy for most patients with limited stage FL. In general, RT is delivered to the involved lymphoid region at a dose of 24 to 30 Gy with an additional 6 Gy administered in select cases, such as those with bulky or slowly regressing disease. Several observational studies have demonstrated that patients with early stage disease treated with radiotherapy have 10-year overall survival rates of 60 to 80 percent, with 10-year relapse-free survival rates of 45 to 60 percent, and median survival of approximately 15 to 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/5,8-14\">",
"     5,8-14",
"    </a>",
"    ]. A subset of patients with limited stage FL may be cured with RT alone.",
"   </p>",
"   <p>",
"    Short- and long-term toxicities associated with RT are dependent upon the site of disease, radiation field, and dose.",
"   </p>",
"   <p>",
"    The following are the largest studies of early stage FL with adequate long-term follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis included 177 patients with stage I (44 percent) or stage II (56 percent) FL treated with RT and followed for a median of 7.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/12\">",
"       12",
"      </a>",
"      ]. Most patients received involved field or extended field RT, with a limited number receiving total lymphoid irradiation. Rates of overall survival and relapse-free survival at 10, 15, and 20 years were 64 and 44 percent, 44 and 40 percent, and 35 and 37 percent, respectively. Freedom from relapse was significantly better for patients under age 60 and for those who received radiation to both sides of the diaphragm, although there was no significant difference in overall survival for these subgroups.",
"     </li>",
"     <li>",
"      A second retrospective study of 80 patients with stage I (33 patients) or II (47 patients) FL treated with radiotherapy followed for a median of 19 years demonstrated no local recurrences more than 17 years after radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/13\">",
"       13",
"      </a>",
"      ]. Cause-specific survival rates at 15 years were 87 and 54 percent for patients with stage I and II disease, respectively. On subset analysis, factors influencing progression-free survival included tumor size and Ann Arbor stage.",
"     </li>",
"     <li>",
"      An analysis of the Surveillance, Epidemiology, and End Results (SEER) database identified 6568 patients with stage I or stage II FL diagnosed from 1973 to 2004, 34 percent of whom were initially treated with RT [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/14\">",
"       14",
"      </a>",
"      ]. When compared with those who did not receive RT, patients who received initial RT had superior rates of disease-specific survival at five (90 versus 81 percent), 10 (79 versus 66 percent), 15 (68 versus 57 percent), and 20 (63 versus 51 percent) years. Overall survival rates were also superior among patients who received initial RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have investigated local RT followed by adjuvant chemotherapy, however, there appears to be no significant advantage of this combined modality approach over local radiotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87718790\">",
"    <span class=\"h3\">",
"     Radiation field",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over time there has been a movement to decrease the field of RT in order to limit acute and long-term toxicities while maintaining response rates. For most patients, we suggest involved field RT rather than extended field RT. TLI is associated with unacceptably high rates of secondary malignancy (up to 17 percent) in this population and is no longer advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. For our discussion, the following definitions apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total lymphoid irradiation (TLI) &mdash; Radiation field includes all lymph nodes, the thymus, and spleen.",
"     </li>",
"     <li>",
"      Extended-field RT &mdash; Radiation field includes not only the clinically involved nodes, but also the adjacent, clinically uninvolved nodes (eg, mantle field or inverted-Y field).",
"     </li>",
"     <li>",
"      Involved-field RT &mdash; Radiation field encompasses all of the clinically involved regions.",
"     </li>",
"     <li>",
"      Involved-node RT &mdash; Radiation field includes nodal volumes plus a margin of healthy tissue &le;5 cm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients treated with involved field or extended field RT generally relapse in contiguous lymphatic sites, in contrast to patients treated with TLI, who generally relapse in extralymphatic sites. A retrospective analysis of 237 patients with stage IA (76 percent) or IIA FL compared involved nodal irradiation (field included involved lymph nodes plus &le;5 cm margins) with involved regional radiation (field included involved lymph nodes plus &ge;1 adjacent uninvolved lymph node groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/20\">",
"     20",
"    </a>",
"    ]. At a median follow-up of 7.3 years, relapse rates and survival rates were similar in the two groups. Prospective trials are required to determine if outcomes are truly similar when the RT field is limited to the involved node alone (ie, involved-node RT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87718783\">",
"    <span class=\"h3\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients, RT is delivered to the involved lymphoid region at a dose of 24 to 30 Gy with an additional 6 Gy administered in select cases, such as those with bulky or slowly regressing disease. Short- and long-term toxicities increase as the dose of radiation increases. As such, attempts have been made to limit the dose of radiation therapy administered to patients with limited stage disease while maintaining efficacy.",
"   </p>",
"   <p>",
"    The importance of radiation dose was examined in a phase III trial that included 261 sites of indolent non-Hodgkin lymphoma (60 percent FL) that randomly assigned radiation at lower doses (24 Gy in 12 fractions) or higher doses (40 to 45 Gy in 20 to 23 fractions) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/21\">",
"     21",
"    </a>",
"    ]. The overall response rate was 93 percent. At a median follow-up of 5.6 years, lower dose radiation resulted in similar rates of in-field progression (hazard ratio 1.09, 95% CI 0.76-1.56), progression-free survival (hazard ratio 1.13, 95% CI 0.73-1.75), and overall survival (hazard ratio 0.96, 95% CI 0.66-1.41).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation with treatment at the time of progression (ie, watch and wait) is an acceptable treatment option for patients with limited stage FL. This is a particularly attractive option if significant morbidity is expected from RT based on the location of the tumor or if the patient chooses against RT.",
"   </p>",
"   <p>",
"    The following are the largest studies that have evaluated this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 43 patients with stage IA or IIA FL observed for at least three months reported a median overall survival of 19.1 years and estimated survival rates at five, 10, and 20 years of 97, 85, and 22 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/22\">",
"       22",
"      </a>",
"      ]. After a median follow-up of 7.2 years, 27 patients (63 percent) had not yet required treatment; the median time to treatment for the other 16 patients was 22 months.",
"     </li>",
"     <li>",
"      Another retrospective analysis of 43 consecutive patients with stage I FL with no residual tumor following the initial diagnostic surgery included 26 patients who were observed initially and 17 who underwent involved field irradiation with or without chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/23\">",
"       23",
"      </a>",
"      ]. After a median follow-up of 6.3 years, 13 of the 26 patients had not relapsed after observation alone. Six had relapsed locally at a median of 4.2 years from diagnosis, all of whom achieved a second complete remission with RT. Seven relapsed in a distant location after a median of one year. Of the patients who underwent initial therapy, none relapsed locally, but seven relapsed at distant sites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These retrospective studies suggest that a percentage of a highly selected patient population may be spared the morbidities associated with RT if observation is used as an initial approach. However, given the potential for cure with RT, we reserve observation for patients who would require RT to areas with high complication rates (eg, the small bowel). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H98998264#H98998264\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Primary intestinal follicular lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chemoimmunotherapy or immunotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy without radiation (RT) has rarely been studied in limited stage FL due to the extreme radioresponsiveness of these tumors. Treatment with chemoimmunotherapy (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus chemotherapy), such as that described for advanced stage disease, or immunotherapy alone may be appropriate for patients with bulky stage II disease or with stage II disease located such that RT would be expected to result in significant morbidity. This approach may also be offered to the patient chooses against RT. (See",
"    <a class=\"local\" href=\"#H87719265\">",
"     'Bulky stage II FL'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the largest uncontrolled prospective observational series, 206 patients with stage I FL confirmed by imaging studies underwent initial management with radiation alone (56 patients), watchful waiting (35 patients),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    alone (25 patients), chemoimmunotherapy (57 patients), or chemoimmunotherapy plus radiation therapy (26 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/4\">",
"     4",
"    </a>",
"    ]. The population that received chemoimmunotherapy with or without radiation therapy included a higher percentage of patients with grade 3 histology (36 percent) than the other groups (11 percent). At a median follow-up of 57 months, 9 of 57 patients (16 percent) treated with chemoimmunotherapy had progressed. Additional follow-up is needed to evaluate long-term disease control and toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Grade IIIb FL",
"    </span>",
"    &nbsp;&mdash;&nbsp;FL tumors are graded on a scale from I to III according to the number of centroblasts per high powered field. Follicular lymphoma grade IIIb (not IIIa) is synonymous with what is often referred to as follicular large cell lymphoma. In contrast to lower grade FLs, this histologic variant has a lesser tendency to involve the bone marrow or peripheral blood and often presents with larger lymphoid masses. Although the follicular architecture is preserved, the clinical presentation, behavior, and outcome with treatment more closely approximates that of the aggressive NHL variant diffuse large B cell lymphoma (DLBCL). Grade IIIb FL is treated according to protocols used for DLBCL. The treatment of DLBCL is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Grade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87719265\">",
"    <span class=\"h2\">",
"     Bulky stage II FL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulky disease refers to a nodal mass with a &gt;10 cm maximum dimension or a mediastinal mass with a maximum width that is equal to or greater than one-third of the internal transverse diameter of the thorax at the level of",
"    <span class=\"nowrap\">",
"     T5/6",
"    </span>",
"    interspace. Clinicians differ in their approach to the management of patients with bulky stage II FL. Some advocate the use of radiation therapy (RT) such as that used for other patients with limited stage FL, while others prefer to manage these patients as advanced FL. A similar divergence in practice is seen in the management of stage II FL that involves multiple sites of disease.",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the management of patients with bulky stage II FL. Subset analyses of trials of RT for stage I or II FL have identified tumor bulk as a marker of worse outcome following RT alone. As an example, in a retrospective analysis of 237 patients with stage I or II FL treated with RT with curative intent, rates of progression-free survival at 10 years decreased with increasing tumor volume (77, 50, and 28 percent for patients with completely excised, &lt;5 cm lesions, and &ge;5 cm lesions, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/20\">",
"     20",
"    </a>",
"    ]. However, rates of overall survival at 10 years did not differ with tumor volume (76, 62, and 78 percent, respectively). It is unknown whether increasing therapy intensity for patients with bulky disease would improve outcomes in this population.",
"   </p>",
"   <p>",
"    A choice among management strategies must take into account the expected side effects of RT given the location of the tumor. If the tumor location is such that toxicities associated with RT are expected to be minimal, initial treatment with RT is reasonable. If the tumor is not amenable to RT, management with immunochemotherapy alone is an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87719229\">",
"    <span class=\"h2\">",
"     Intrafollicular neoplasia (\"in-situ\") FL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrafollicular neoplasia is a pathologic diagnosis used to describe the identification of follicles, typically several in number, that have a high content of BCL-2-positive B cells within a lymph node that otherwise lacks the diagnostic features of FL. Little is known regarding the natural history of patients with this finding who have no evidence of FL on further evaluation. A retrospective analysis of 21 cases of in situ FL with a median follow-up of 41 months reported only one case of progression to disseminated FL [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/24\">",
"     24",
"    </a>",
"    ]. Such patients are not considered as having a diagnosis of FL. Following removal of the involved lymph node, these patients should be followed clinically for evidence of progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Intrafollicular neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87718797\">",
"    <span class=\"h2\">",
"     Primary intestinal FL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary intestinal FL is a rare variant of FL characterized by lymphomatous disease pathologically consistent with FL confined to the intestine without lymph node involvement. The management of primary intestinal FL must take into account the significant morbidity associated with radiation of the small bowel. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H98998264#H98998264\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Primary intestinal follicular lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87719351\">",
"    <span class=\"h2\">",
"     Primary cutaneous FL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous follicle center lymphoma is a unique clinicopathologic entity similar to FL that presents in the skin without evidence of extracutaneous disease at the time of diagnosis and after the completion of an initial staging evaluation. The diagnosis and treatment of primary cutaneous follicle center lymphoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"     \"Primary cutaneous follicle center lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EVALUATION OF RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). The post-treatment imaging study of choice for most patients is the CT scan. CT should be obtained six to eight weeks after completion of chemotherapy, and 12 weeks after the completion of radiation therapy.",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and CT scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/25\">",
"     25",
"    </a>",
"    ]. While the goal of treatment is a complete remission (CR), many patients only obtain a partial remission (PR).",
"   </p>",
"   <p>",
"    A CR has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All lymph nodes are of normal size on CT.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pre-treatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A PR is defined as at least a 50 percent decrease in the cumulative size of involved nodes, splenic lesions, and hepatic nodules. There must be no new sites of disease and no increase in the size of any node, the liver, or spleen.",
"   </p>",
"   <p>",
"    Patients who fail to obtain a PR have refractory disease. Treatment of refractory disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of combined positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT",
"    </span>",
"    in the response assessment of FL remains to be determined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The utility of",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      was assessed as a secondary analysis in the prospective Primary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      and Maintenance (PRIMA) study of rituximab plus chemotherapy in patients with advanced stage FL [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/26\">",
"       26",
"      </a>",
"      ]. In this study, of 122",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scans performed after the completion of immunochemotherapy, 32 (26 percent) were positive. PET status correlated with conventional response criteria and was an independent predictive factor for lymphoma progression. When compared with patients with negative PET scans, patients with positive PET scans following treatment had inferior progression-free survival at 42 months (33 versus 71 percent). Response evaluation that incorporated PET resulted in a change of response status expected to change treatment in two patients.",
"     </li>",
"     <li>",
"      In another prospective study, PET scans were performed following immunochemotherapy in 121 patients with previously untreated &ldquo;high tumor burden&rdquo; FL as defined by the presence of at least one of the following: bulky disease (one lesion &gt;7 cm); three separate nodes &ge;3 cm; symptomatic splenomegaly; organ compression by tumor; pleural or peritoneal effusion; raised LDH or beta-2-microglobulin; or B symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/27\">",
"       27",
"      </a>",
"      ]. PET scans were centrally reviewed, while conventional staging studies (CT, clinical examination, bone marrow) were not. Physicians were not blinded to the PET results, but were instructed to avoid using PET results to make treatment decisions. Only one of the 54 patients who achieved a CR by conventional staging had a positive PET scan. In contrast, half of the patients achieving a CRu (CR, unconfirmed) and 34 percent of those with a PR had a positive PET scan. When compared with a negative PET, a positive PET scan was associated with a worse progression-free survival (51 versus 87 percent) and overall survival (88 versus 100 percent) at two years. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that a combined",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan may provide additional prognostic information for patients with high tumor burden at the time of diagnosis who do not achieve a CR by conventional criteria. Prospective trials are needed to determine whether changes to therapy made based upon PET results could impact patient important outcomes. We do not advocate the use of PET imaging in this setting outside of a clinical trial.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     BCL-2/IgH",
"    </span>",
"    translocation [eg, t(14;18)] can identify follicular lymphoma tumor cells. Some studies have reported improved clinical outcomes for those patients who attain polymerase chain reaction (PCR) negativity after induction therapy, while others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. As an example, one study incorporated PCR testing into the evaluation of 238 patients enrolled in a randomized intergroup trial of CHOP chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9865/abstract/31\">",
"     31",
"    </a>",
"    ]. For patients who obtained a CR or PR, progression-free survival rates were similar in patients who obtained PCR negativity and those who were still PCR positive at the end of induction therapy. At present, PCR testing for this translocation should not be routinely performed.",
"   </p>",
"   <p>",
"    The accuracy of imaging tests in the follow-up of patients with lymphoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete or partial remission, patients are seen at periodic intervals to monitor for treatment complications and assess for progression. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up.",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every three months during the first year and then every three to six months thereafter. At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH. The role of routine imaging in the longitudinal follow-up of asymptomatic patients after response assessment is uncertain.",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. In addition, biopsy evaluates for histologic transformation to more aggressive disease. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. The treatment of relapsed FL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients treated for FL require surveillance for potential long-term toxicities. The long term care of the non-Hodgkin lymphoma survivor is presented separately, focusing on issues that require attention at approximately five years from the completion of therapy onwards. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4185?source=see_link\">",
"     \"Overview of care for adult survivors of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better strategy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FL generally have an excellent prognosis; however, there are groups of patients who have more as well as less favorable survival. The Follicular Lymphoma International Prognostic Index (FLIPI) (",
"    <a class=\"graphic graphic_table graphicRef55987 \" href=\"UTD.htm?36/23/37243\">",
"     table 2",
"    </a>",
"    ) was developed specifically for patients with FL, since the International Prognostic Index, which was developed in patients with aggressive NHL, resulted in conflicting results, due in large part to a low number of patients with clinically indolent lymphoma (approximately 10 percent) belonging to the higher risk groups.",
"   </p>",
"   <p>",
"    This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H75814042#H75814042\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Follicular lymphoma IPI (FLIPI)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     HISTOLOGIC TRANSFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An integral part of the natural history of FL is progression to a higher grade histologic subtype, such as diffuse large B cell lymphoma. As detailed separately, a subgroup of patients with FL who transform to a more aggressive histology may attain complete remission following treatment with CHOP-like chemotherapy, and some may be cured by high dose chemotherapy followed by autologous hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link&amp;anchor=H179016843#H179016843\">",
"     \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'Following histologic transformation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=see_link\">",
"       \"Patient information: Follicular lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=see_link\">",
"       \"Patient information: Follicular lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma. Treatment of FL depends upon the stage of disease at presentation as evaluated by the Ann Arbor Staging system (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A pre-treatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. Enrollment in clinical trials should be encouraged. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pre-treatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited stage FL is that which is limited to a single lymph node region (stage I), single extralymphatic organ or site (stage IE), or more than one lymph node or lymphatic structure on the same side of the diaphragm alone (stage II) or with involvement of a limited, contiguous extralymphatic organ or tissue (stage IIE) (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For most patients with stage I or nonbulky stage II FL, we suggest initial treatment with radiation therapy rather than treatment with chemotherapy or an initial period of observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is principally based upon the observation that some patients may be cured with radiation therapy. If significant morbidity is expected from radiotherapy based on the location of the tumor, or if the patient chooses against radiotherapy, a management approach similar to that used for advanced stage disease may be a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H19679373\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation therapy is delivered to the involved lymphoid region at a dose of 24 to 30 Gy with an additional 6 Gy administered in select cases, such as those with bulky or slowly regressing disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommendations presented here pertain to most patients with FL. Patients with certain clinical presentations or histologic features require specific attention:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with grade IIIb FL are treated as patients with aggressive lymphomas (eg, diffuse large B cell lymphoma). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Grade IIIb FL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians differ in their approach to the management of patients with bulky stage II FL. Some advocate the use of radiation therapy such as that used for other patients with limited stage FL, while others prefer to manage these patients as advanced FL. While increasing tumor mass is a marker of poor outcome, it is unknown whether increasing therapy intensity for patients with bulky disease would improve outcomes in this population. (See",
"      <a class=\"local\" href=\"#H87719265\">",
"       'Bulky stage II FL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrafollicular neoplasia is a pathologic diagnosis used to describe the identification of follicles, typically several in number, that have a high content of BCL-2-positive B cells within a lymph node that otherwise lacks the diagnostic features of FL. Following removal of the involved lymph node, these patients should be followed clinically for evidence of progression. (See",
"      <a class=\"local\" href=\"#H87719229\">",
"       'Intrafollicular neoplasia (\"in-situ\") FL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with primary intestinal FL or primary cutaneous follicle center lymphoma is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"       \"Primary cutaneous follicle center lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H98998264#H98998264\">",
"       \"Management of gastrointestinal lymphomas\", section on 'Primary intestinal follicular lymphoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are evaluated after treatment with laboratory studies and a computed tomography in addition to a history and physical examination to determine response to therapy. Patients attaining a complete or partial remission are followed at periodic intervals for disease progression. Patients who fail to achieve a partial remission are treated as refractory disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Evaluation of response to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Surveillance for relapse'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19677745#H19677745\">",
"       \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Surveillance for relapse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/1\">",
"      Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/2\">",
"      Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/3\">",
"      Krikorian JG, Portlock CS, Cooney P, Rosenberg SA. Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer 1980; 46:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/4\">",
"      Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012; 30:3368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/5\">",
"      Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/6\">",
"      Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:2115.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on June 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/8\">",
"      Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer 1979; 43:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/9\">",
"      McLaughlin P, Fuller LM, Velasquez WS, et al. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/10\">",
"      Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003; 57:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/11\">",
"      Zhou P, Ng AK, Silver B, et al. Radiation therapy for orbital lymphoma. Int J Radiat Oncol Biol Phys 2005; 63:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/12\">",
"      Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/13\">",
"      Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/14\">",
"      Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer 2010; 116:3843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/15\">",
"      Monfardini S, Banfi A, Bonadonna G, et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1980; 6:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/16\">",
"      Toonkel LM, Fuller LM, Gamble JF, et al. Laparotomy staged I and II non-Hodgkin's lymphomas: preliminary results of radiotherapy and adjunctive chemotherapy. Cancer 1980; 45:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/17\">",
"      Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 1994; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/18\">",
"      Murtha AD, Rupnow BA, Hansosn J, et al. Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys 2001; 49:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/19\">",
"      Lybeert ML, Meerwaldt JH, Deneve W. Long-term results of low dose total body irradiation for advanced non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 1987; 13:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/20\">",
"      Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116:3797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/21\">",
"      Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/22\">",
"      Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/23\">",
"      Soubeyran P, Eghbali H, Trojani M, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 1996; 7:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/24\">",
"      Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011; 118:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/25\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/26\">",
"      Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011; 29:3194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/27\">",
"      Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 2012; 30:4317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/28\">",
"      Czuczman MS, Grillo-L&oacute;pez AJ, McLaughlin P, et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001; 12:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/29\">",
"      Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/30\">",
"      L&oacute;pez-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/31\">",
"      van Oers MH, T&ouml;nnissen E, Van Glabbeke M, et al. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 2010; 28:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9865/abstract/32\">",
"      Goff L, Summers K, Iqbal S, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 2009; 27:6094.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4741 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9865=[""].join("\n");
var outline_f9_40_9865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H841817\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRE-TREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19679373\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87718790\">",
"      - Radiation field",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87718783\">",
"      - Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chemoimmunotherapy or immunotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Grade IIIb FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87719265\">",
"      Bulky stage II FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87719229\">",
"      Intrafollicular neoplasia (\"in-situ\") FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87718797\">",
"      Primary intestinal FL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87719351\">",
"      Primary cutaneous FL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EVALUATION OF RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      HISTOLOGIC TRANSFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/23/37243\" title=\"table 2\">",
"      Follic lymphoma int prog index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 3\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 5\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=related_link\">",
"      Hematopoietic cell transplantation in follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4185?source=related_link\">",
"      Overview of care for adult survivors of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=related_link\">",
"      Pathobiology of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=related_link\">",
"      Patient information: Follicular lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=related_link\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_40_9866="Adolescent sexuality";
var content_f9_40_9866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adolescent sexuality",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9866/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9866/contributors\">",
"     Michelle Forcier, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9866/contributors\">",
"     Robert Garofalo, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9866/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/40/9866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/40/9866/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/40/9866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;From Aristotle's early treatises on sexual desire to Sigmund Freud's theories of psychosocial development, adolescent sexuality has been a controversial topic for virtually every generation. As the 21",
"    <sup>",
"     st",
"    </sup>",
"    century unfolds, society will continue to be challenged by adolescent sexual behavior and its consequences. Although medical providers often discuss adolescent sexuality in terms of \"risk\", it is important to remember that sexuality, sexual behaviors, and sexual relationships are an important and necessary part of human development. Responsible sexual behavior (eg, delaying initiation of sexual intercourse, choosing caring and respectful partners, increasing the use of condoms, and using effective contraception) is an important public health issue. The United States Healthy People 2020 goals include improved pregnancy planning and spacing; prevention of unintended pregnancy; promotion of healthy sexual behaviors; and increased access to quality services to prevent sexually transmitted diseases and their complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The World Health Organization and other agencies interested international health also identify adolescent-friendly health services as a worldwide priority [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], with 70 percent of more than 1 billion youth (10 to 19 years) living in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among adolescents in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young women reach puberty and sexual maturity (eg, breast development, menarche) at earlier ages than ever [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"       \"Normal puberty\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"       \"Definition, etiology, and evaluation of precocious puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately one-half of high school youth report having had sexual intercourse, and one-third report being currently sexually active [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/7\">",
"       7",
"      </a>",
"      ]. Prevalence of sexual activity increases with age, rising from 33 percent in 9",
"      <sup>",
"       th",
"      </sup>",
"      graders to 63 percent in 12",
"      <sup>",
"       th",
"      </sup>",
"      graders [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trends (from 1991 to 2011) in the Youth Risk Behavior Survey indicate that [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/8\">",
"       8",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rates of sexual activity have decreased (54 to 47 percent)",
"     </li>",
"     <li>",
"      Rates of sex with more than four persons have decreased (19 to 15 percent)",
"     </li>",
"     <li>",
"      Rates of condom use at last intercourse increased from 1991 to 2003 (46 to 63 percent) but remained stable from 2003 to 2011 at 60 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite increases in the rate of condom use by teens in the 1990s, one-fourth of sexually transmitted infections (STI) each year occur in young people aged 15 through 24 years; youth are over-represented, accounting for almost one-half of new infections [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/9\">",
"       9",
"      </a>",
"      ]. Human papillomavirus (HPV),",
"      <em>",
"       Chlamydia",
"      </em>",
"      , and trichomoniasis, account for almost 90 percent of STIs in this age group [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/9\">",
"       9",
"      </a>",
"      ]. One in four young women ages 14 to 19 is infected with at least one of four STI (HPV,",
"      <em>",
"       Chlamydia",
"      </em>",
"      , herpes simplex virus (HSV), and trichomoniasis) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 5 percent of teens identify as lesbian, gay, or bisexual [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/10\">",
"       10",
"      </a>",
"      ]. Over 10 percent of females and between 2 and 6 percent of males report having participated in same-gender sexual activity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/7\">",
"       7",
"      </a>",
"      ]. Adolescents' uncertainty about their sexual orientation decreases with age, from 26 percent of 12-year-old students to 5 percent of 17-year-olds [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/11\">",
"       11",
"      </a>",
"      ]. Adolescents with both male and female sexual partners have higher rates of unprotected sex, teen dating violence (TDV), and forced sex [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/12\">",
"       12",
"      </a>",
"      ]. Gender variant adolescents seem to experience similar difficulties including higher risks of bullying, social isolation, and suicidality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As adolescents struggle to understand their emerging sexualities within the context of their complex social environments, the challenge for health care providers is to provide adolescents with the necessary anticipatory guidance to maintain optimal sexual health and to help adolescents avoid behaviors and expression that place them at risk for negative consequences. Understanding sexuality as a normal and necessary part of adolescent development can help providers use a strength-based approach when counseling adolescents. Appropriate screening, education, and support can empower and encourage teens to make healthy safer sexual decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Additional anticipatory guidance topics for adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=see_link\">",
"     \"Guidelines for adolescent preventive services\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human sexuality is a broad concept that embodies interaction among anatomy, hormones, and physiology, psychology, interpersonal relationships, and sociocultural influences (",
"    <a class=\"graphic graphic_figure graphicRef50053 \" href=\"UTD.htm?38/46/39649\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/14\">",
"     14",
"    </a>",
"    ]. Approaching sexuality as a paradigm of intersecting factors between gender and sex can help providers begin to appreciate the complexities of the developing adolescent sexuality. Understanding terminology and distinctions between seemingly similar constructs is helpful in providing appropriate patient care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Biologic, anatomic, or natal sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic, hormonal, and anatomic characteristics determine whether a person is a biologic female or male. Biologic sex typically is defined by medical assessment of genitalia during infancy. Children then are reared according to their biologically or anatomically assigned sex, with little additional thought given to the individual's psychological or behavioral self-identification [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/15\">",
"     15",
"    </a>",
"    ]. Anatomic sex usually is viewed as a binary concept, male or female. Rare individuals harbor both male and female gonadal tissue (ovotesticular disorder of sexual development). Patients with disorders of sexual development may have subtle or obvious genital abnormalities that present during the newborn period, childhood, or adolescence. Disorders of sexual development are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"     \"Evaluation of the infant with ambiguous genitalia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link\">",
"     \"Management of the infant with ambiguous genitalia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=see_link\">",
"     \"Diagnosis and treatment of disorders of the androgen receptor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=see_link\">",
"     \"Steroid 5-alpha-reductase 2 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender, gender identity, gender role, and gender expression are personal, psychological, and cultural constructs referring to various aspects of maleness and femaleness. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Gender identity",
"      </strong>",
"      is an individual's innate sense of being male, female, or somewhere in between [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/16\">",
"       16",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Gender role",
"      </strong>",
"      is society&rsquo;s expectations of attitudes, behaviors, and personality traits typically based on biologic sex. Masculinity and femininity are main concepts conveying these cultural associations.",
"     </li>",
"     <li>",
"      <strong>",
"       Gender expression",
"      </strong>",
"      is how gender is presented to the outside world but does not necessarily correlate with gender identity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An individual's gender identity is generally established at some point during early childhood. Rather than a binary concept with fixed opposites",
"    <span class=\"nowrap\">",
"     (male/female),",
"    </span>",
"    gender may also be viewed along a continuum, depending upon individual or social interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Current models of gender theory move beyond two dimensions and include variations of self identification and terminology such as: gender variance, gender queer, gender fluid, two spirit, or transgender. In general,",
"    <strong>",
"     transgender",
"    </strong>",
"    refers to individuals whose gender role or gender identity is not congruent with their biologic or anatomically assigned sex [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=see_link\">",
"     \"Transsexualism: Epidemiology, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sexual orientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual orientation refers to an individual's pattern of physical and emotional arousal (including fantasies, activities, and behaviors) and the gender(s) of persons to whom an individual is physically or sexually attracted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/16\">",
"     16",
"    </a>",
"    ]. An individual person&rsquo;s assessment of her or his sexual orientation is termed sexual identity. Sexual behavior alone is neither a sensitive nor a specific predictor of adolescent gender identification, sexual orientation, or sexual identity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/21\">",
"     21",
"    </a>",
"    ]. In the 2005-2007 New York City Youth Risk Behavior Surveys, 39 percent of adolescents with only same or both sex partners self-identified as heterosexual or straight [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/12\">",
"     12",
"    </a>",
"    ]. Formation of sexual identity among youth often is fluid, and experimentation with same-gender sexual contacts can be part of healthy adolescent development [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/22\">",
"     22",
"    </a>",
"    ]. Heterosexual youth may experiment with same-gender sexual partners. Homosexual youth may have opposite-gender sexual partners. Either group may abstain from sexual activity altogether.",
"   </p>",
"   <p>",
"    In the 1950s, Kinsey maintained that, though commonly dichotomized into heterosexual or homosexual, many individuals' sexual orientation lies somewhere in between, not absolutely one or the other [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/23\">",
"     23",
"    </a>",
"    ]. Considerable debate persists about Kinsey's hypothesis with increasing sophistication about the specific elements of \"nature\" versus \"nurture\" determinants of gender identity and sexual orientation. Prenatal exposure to androgens, neurologic structures and functions, and other neurophysiologic theories are currently linked to both gender development and sexual orientation, though in ways that are not entirely clear. Genetics, male birth order, and immunology are among biologic factors additionally being studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8879340\">",
"    <span class=\"h1\">",
"     SEXUALITY AND SOCIETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding distinctions between gender, sexual orientation, and sexual behavior is a critical concept in adolescent health and is influenced greatly by the culture in which one lives [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/14\">",
"     14",
"    </a>",
"    ].&nbsp;An individual's impression of gender or sexuality often is conveyed first to him or her by parents during early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/24\">",
"     24",
"    </a>",
"    ]. Parents or other immediate family members help children define what is male and female and how they express themselves as members of their gender. Some authors argue that social environments after birth may have little or no impact on gender identity or sexual orientation, with prenatal hormones having major effects on organizing developing sexuality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    As children become adolescents, influences broaden with peer, media, and community norms of gender and sexuality impacting their individual value systems. Media exerts a powerful influence on adolescents and their perception of gender roles and sexual behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/26\">",
"     26",
"    </a>",
"    ]. American adolescents are exposed to several hours of media (television, radio, Internet) each day, during which they experience significant exposure to sexual content, which often contains implicit and explicit references to intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Electronic media and social networking provide adolescents with even more ways to explore their burgeoning sexuality. Online social networking sites for adolescents frequently mention or feature sex and sexual behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In a national survey of US teenagers (ages 13 to 19), 20 percent self-reported sending and 48 percent reported receiving sexual messages [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/33\">",
"     33",
"    </a>",
"    ]. Longitudinal research consistently links degree of exposure to sexuality in the media to increased sexual risk taking and adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adolescent sexuality occurs in the context of many other aspects of adolescent development and is more complicated for sexual minorities or lesbian, gay, bisexual, transgender, queer, or questioning (LGBTQQ) youth. Regardless of the acronyms and current issues in terminology, the individual youth is the person best suited to describe and define identity and behaviors. Many youth refuse categorization, preferring more diffuse terminology such as gender queer, queer, pansexual, or fluid regarding gender and sexuality. What matters for most youth is that the provider asks about their personal perspective, experience, and what terminology best suits their needs.",
"   </p>",
"   <p>",
"    Problems may arise for adolescents who encounter conflict between their emerging sexuality and the approach to sexuality they experience from families, peers, culture, and society as a whole. Role modeling, sex education, and other information for developing adolescents often has a solely heterosexual focus, with homosexuality considered a social or religious taboo. Family connectedness, social support at school, community support for its lesbian, gay, bisexual, transgender, queer, or questioning members, as well as a strong caring adult mentor seem to provide some resiliency and protectedness for sexual minority youth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADOLESCENT DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;General adolescent development is frequently divided into three stages based loosely on chronologic age and level of functioning: early, middle, and late adolescence (",
"    <a class=\"graphic graphic_table graphicRef79899 \" href=\"UTD.htm?38/28/39371\">",
"     table 1",
"    </a>",
"    ). One of the tasks for healthy adolescent development is the acquisition of a mature and responsible sexual identity including both an expression of sexual behaviors and the capacity for meaningful intimate relationships.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Early adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early adolescence (ages 10 to 14) coincides with the onset of puberty and typically involves concrete thinking, preoccupations and insecurities surrounding the physical changes of the body, and an egocentric approach to sexuality. Sexual curiosity and exploration may lead to initiating sexual experimentation with masturbation, or early sexual activity with same- or opposite-gender sexual partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Middle adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle adolescents (ages 15 to 18) complete the physical changes of puberty and begin to have more romantic relationships typically characterized by serial monogamy or having several partners at once and over brief periods of time. Middle teens can begin to imagine the consequences of their actions but still may not fully understand them and, because of this, engage in risk-taking behaviors such as substance use and unprotected sexual activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Late adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late adolescents (ages 18 and up) have more mature social skills, empathy, and an understanding of risks and consequences that help them develop more intimate and serious relationships. They have a mature understanding and enjoyment of their physical self, gender role, sexual orientation, and sexual behaviors. They can participate in a variety of intimate and social relationships (romantic partners, friends, family, professional colleagues) with a broader sense of connection and purpose in the community.",
"   </p>",
"   <p>",
"    Adolescents or young adults who are mature and healthy in their sexuality are able to [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify and live according to one&rsquo;s own values; take responsibility for one&rsquo;s own behavior",
"     </li>",
"     <li>",
"      Practice effective decision-making; develop critical-thinking skills",
"     </li>",
"     <li>",
"      Affirm that human development includes sexual development, which may or may not include reproduction or sexual experience",
"     </li>",
"     <li>",
"      Seek further information about sexuality and reproduction as needed and make informed choices about family options and relationships",
"     </li>",
"     <li>",
"      Interact with all genders in respectful and appropriate ways",
"     </li>",
"     <li>",
"      Affirm one&rsquo;s own gender identity and sexual orientation and respect the gender identities and sexual orientations of others",
"     </li>",
"     <li>",
"      Appreciate one&rsquo;s body and enjoy one&rsquo;s sexuality throughout life, expressing one&rsquo;s sexuality in ways that are congruent with one&rsquo;s values",
"     </li>",
"     <li>",
"      Express love and intimacy in appropriate ways",
"     </li>",
"     <li>",
"      Develop and maintain meaningful relationships, avoiding exploitative or manipulative relationships",
"     </li>",
"     <li>",
"      Exhibit skills and communication that enhance personal relationships with family, peers, and romantic partners",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEALTH ISSUES AND OUTCOMES RELATED TO SEXUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual behaviors in teens include a range of activities from kissing, petting, and fondling to oral, anal, and vaginal sex. While vaginal-penile intercourse, with its inherent risks for pregnancy and sexually transmitted infection (STI), has been the best researched, many of these other sexual behaviors may serve as a prelude to intercourse or substitute for intercourse for teens wishing to preserve their \"virginity\". Teens engaging in oral sex are likely to initiate vaginal sex soon after; in a prospective study, 50 percent of high school",
"    <span class=\"nowrap\">",
"     freshmen/sophomores",
"    </span>",
"    who initiated oral sex at the end of ninth grade self-reported engaging in vaginal sex within the next two years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating teen sexual behaviors are fraught with problems regarding reliability and consistency of reported behaviors, definitions and understanding of specific behaviors, difficulties in measuring activities, and the impact of these activities on their current and future lives. Many studies indicate high levels of inconsistent reporting for sensitive, sexually related behaviors including dating, abstinence, first sexual intercourse, risk for STIs, and experiences with abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. Statistics and trends in sexual activity, behaviors, and outcomes are helpful to clinicians and impact screening and decision making. However, it is more crucial for clinicians to understand the multifaceted nature and complexity of sexuality as teens explore their gender and sexual identity in ways that are respectful, healthy, and safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unplanned pregnancy, childbirth, and parenting are significant consequences of adolescent sexual activity. The majority of adolescent pregnancies are unplanned, disproportionately accounting for greater than one-fifth of all unintended pregnancies each year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/44\">",
"     44",
"    </a>",
"    ]. Consequences of early and unplanned pregnancy are several-fold. Pregnant adolescents are more likely to delay seeking prenatal care and have higher rates of unfavorable birth outcomes, such as prematurity, infant mortality, and poor health and developmental outcomes. In addition, adolescent mothers are more likely to drop out of school, face unemployment, live in poverty, and rely on public assistance than are their peers who do not have children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=see_link&amp;anchor=H12#H12\">",
"     \"Pregnancy in adolescents\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Almost one-half of unintended pregnancies occur among users of contraception and are due to difficulties with adherence and continuation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/45\">",
"     45",
"    </a>",
"    ]. Additionally, suboptimal contraceptive use is consistently associated with pregnancy ambivalence in both teens and adult women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/46\">",
"     46",
"    </a>",
"    ]. Providers can better assist young women avoid unintended pregnancy by regularly assessing adherence, continuation, and perceived and real side effects. Identifying young women at risk for inconsistent contraceptive use because of disadvantage, intermittent sexual activity, or ambivalence about pregnancy intention permits more tailored counseling and contraception planning. It is important not to assume that every teen wants to avoid pregnancy. Asking about immediate and long-term family planning and encouraging a teen to openly discuss pregnancy ambivalence or intention may allow more realistic anticipatory sexual health guidance, which may include pre-conceptual counseling as well as contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraceptive counseling, including discussion of abstinence, is a critical component of any comprehensive pregnancy and STI prevention strategy. Abstinence is the single most effective means to avoid pregnancy, and support is warranted for adolescents who decide to abstain from sexual activity. However, for adolescents who choose to be sexually active, there are many effective methods of contraception. Long-acting reversible contraceptives, such as the intrauterine device and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant, are highly efficacious methods that have been recommended as first line contraceptive options for nulliparous teens and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"     \"Contraception: Overview of issues specific to adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confidentiality and availability of teen-friendly family-planning counseling and options are critical factors in getting adolescents to use contraception consistently and effectively. It is important to discuss contraception with both male and female adolescents, engaging young men in family planning decision making. Additionally, many young women who have sex with women also have sex with male partners and should be offered education and methods of contraception and STI prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     STIs and HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 19 million STIs occur each year in the United States, of which a disproportionate number (9 million) occur in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/9\">",
"     9",
"    </a>",
"    ]. STIs and HIV in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1737?source=see_link\">",
"     \"The adolescent with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    STIs are a disease of adolescents and young adults. The CDC considers adolescents a special population in their regular review of STI care in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/48\">",
"     48",
"    </a>",
"    ]. Infections with human papillomavirus,",
"    <em>",
"     Chlamydia",
"    </em>",
"    , and gonorrhea have the highest rates in teens and young adults. Multiple aspects of adolescence contribute to this increased risk including: early sexual debut, multiple sexual partners, sequential sexual partnerships of limited duration, inconsistent condom use, increased biologic susceptibility to infection, and difficulties accessing health care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/49\">",
"     49",
"    </a>",
"    ]. Youth at highest risk for STIs include those in juvenile detention facilities, young men having sex with men and youth using injection drugs.",
"   </p>",
"   <p>",
"    In the United States, all 50 states and the District of Columbia explicitly protect minors&rsquo; rights to confidential services and care for STIs. Despite these protections and the high rates of STIs in this age group, many providers fail to routinely assess STI risks, provide harm reduction counseling, and screen for asymptomatic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Screening for STIs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    STI prevention counseling should be developmentally appropriate (",
"    <a class=\"graphic graphic_table graphicRef85699 \" href=\"UTD.htm?13/7/13438\">",
"     table 2",
"    </a>",
"    ) and provide anticipatory education and guidance, with a goal of risk avoidance and harm reduction. Open-ended questions and nonjudgmental counseling is important for adolescents who may not fully report all risks and sexual behaviors. Because early age of first intercourse is a risk factor for pregnancy and STI acquisition, it is appropriate to support abstinence and delaying sexual debut. For those who choose to be sexually active, consistent and correct use of condoms is the most effective strategy to prevent STIs. When recommending condoms, it is important for providers to demonstrate appropriate techniques for condom use and to model effective communication and partner negotiation skills. These goals (abstinence or consistent use of condoms) may be difficult to achieve for adolescents who feel invulnerable and who may lack cognitive risk-consequence decision-making abilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45216050\">",
"    <span class=\"h2\">",
"     Sexual victimization",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45216087\">",
"    <span class=\"h3\">",
"     Teen dating violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teen dating violence (TDV), including psychological, physical, and sexual aggression is common in adolescent dating relationships with rates highest in young women ages 16 to 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/52\">",
"     52",
"    </a>",
"    ]. In 2011, approximately 9 percent of all high school adolescents reported some form of physical violence in their romantic relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/8\">",
"     8",
"    </a>",
"    ]. TDV is more common in teens engaging in other risk activities such as drug and alcohol use, suicidal ideation, and unprotected sex [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/53\">",
"     53",
"    </a>",
"    ]. Adolescent males and females report perpetration and victimization from violence equally. While TDV has this bidirectional quality, adolescent females perpetrate less severe and less physical violence and suffer more psychological sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/54\">",
"     54",
"    </a>",
"    ]. Medical providers who do not routinely screen for TDV in adolescents miss opportunities for education and intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15561?source=see_link\">",
"     \"Date rape: Identification and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=see_link\">",
"     \"Date rape: Risk factors and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45216032\">",
"    <span class=\"h4\">",
"     Sexual minority youth",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial research documenting increased risk behaviors, victimization, and adverse health outcomes among gender non-conforming and sexual minority youth. Health risks and adverse outcomes include child abuse, bullying, sexual harassment, TDV, mental health problems (depression, anxiety, suicide, disordered eating and body image), substance use, and unprotected sex with risks for sexually transmitted infections and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/55\">",
"     55",
"    </a>",
"    ]. Teens who identify as having partners of both sexes seem to be at highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/12\">",
"     12",
"    </a>",
"    ]. Chronic victimization has additional effects because young men having sex with men who have been repeatedly victimized are less likely to request that their partners use a condom [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to ask about sexual partners and behaviors in order to screen and offer anticipatory guidance. Assuming that risks and outcomes are more related to gender of partners than to social support for sexual minorities, quality of sexual experience, and self esteem may do a significant disservice to youth. By promoting sexuality as normative, healthy, respectful, and meaningful in the global context of adolescent development, providers can encourage a positive model of empowerment, strength, and resiliency for all youth exploring their gender and sexual identities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEALTH CARE PROVIDER ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sex education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education and interventions that promote responsible and healthy sexuality can and should be delivered in homes, schools, medical, and community settings. Despite a movement to provide abstinence-only education, evidence continues to demonstrate that abstinence-only programs do not work, that comprehensive sexuality education programs can improve knowledge and reduce risk behaviors, and that the public and parents support comprehensive programs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/58-63\">",
"     58-63",
"    </a>",
"    ]. Comprehensive information with motivational and skills-based content is successful in reducing penetrative sexual behaviors and improving condom negotiation and use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. There is copious evidence demonstrating that comprehensive sexual education delays intercourse, reduces frequency of intercourse, reduces the number of sexual partners, and increases the use of condoms and other contraceptives after sexual debut [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/66\">",
"     66",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    School-based interventions have been the traditional source of mass sexual health education efforts. The most effective programs have common characteristics: clear health goals",
"    <span class=\"nowrap\">",
"     (STI/HIV",
"    </span>",
"    prevention or pregnancy prevention), explicit linking of behavior to goals (abstinence, condom use), and strategies to improve sexual decision making and behaviors (knowledge, attitudes, values, perception of risk, community norms, self-efficacy) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/67\">",
"     67",
"    </a>",
"    ]. Teens today, however, report that their education about sexual health comes from a variety of sources. Sex education from parents, grandparents, and religious leaders has been associated with beliefs linked to delaying sex [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/68\">",
"     68",
"    </a>",
"    ]. Learning about sex from friends, cousins, and the media has been linked to beliefs increasing the likelihood of engaging in sex [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/69\">",
"     69",
"    </a>",
"    ]. The focus on abstinence-only education has led to the media serving as a leading sex &ldquo;educator&rdquo; in the United States today [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/70\">",
"     70",
"    </a>",
"    ], especially for younger sexually inexperienced teens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the importance of media and technology in youth culture, it is important for newer frameworks of health education to consider alternative electronic routes such as interactive computer modules, text messaging, and other social media networks as well as school-based lecture style interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. As often as STIs and early pregnancy have been studied in youth populations, there are still many opportunities to learn more about health promotion and harm reduction in some of the highest risk youth, including those who are incarcerated, have mental illness, trade sex for resources, or are HIV-positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barriers to discussions of sexuality include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinic and service accessibility (hours of operation, transportation, insurance, billing, or self-pay costs)",
"     </li>",
"     <li>",
"      Lack of or perceived lack of confidentiality",
"     </li>",
"     <li>",
"      Mandatory parental consent laws or practices related to contraception, sexually transmitted infections, etc (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"       \"Confidentiality in adolescent health care\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lack of communication coordination among and between health programs",
"     </li>",
"     <li>",
"      Narrowed, personally biased conception of sexual health care and lack of evidence based information negatively impacting clinician anticipatory guidance and prevention efforts",
"     </li>",
"     <li>",
"      Provider- or system-level political, religious and ethical beliefs and biases",
"     </li>",
"     <li>",
"      Stigma and discomfort associated with various aspects of sexuality including specific sexual behaviors, gender and sexual variance, and early sexual activity",
"     </li>",
"     <li>",
"      Practical and financial constraints of clinic time and resources",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many health care providers miss opportunities to discuss gender and sexual health issues. Abstinence, condom use, and STI prevention are routinely discussed in over one-half of anticipatory guidance visits. However, this is well below the recommendation of universal annual screening and education. Screening and counseling in regards to sexual orientation, gender identity, and a complete range of contraceptive options for adolescents is markedly below national goals and recommended standards of care [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/51,76\">",
"     51,76",
"    </a>",
"    ]. Providers who are uncomfortable or unable to provide comprehensive adolescent sexual health care may consider referring their patients to a provider who specializes in adolescent medicine. Comprehensive sexual health education and support can be complex and time consuming, necessitating referral to additional resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Principles of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers play an important role for youth in discussions of adolescent health and sexuality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/16,77,78\">",
"     16,77,78",
"    </a>",
"    ]. Many adolescents consider their provider to be the most valued and trusted source of advice about issues of health and sexuality. Medical providers are particularly important facilitators of sexual health discussions as many youth indicate that they \"definitely would not\" talk to parents, citing \"embarrassment\" as the main reason to avoid discussion, with least communication occurring between fathers and daughters [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians who provide adolescent sexual health care often use interview techniques and care paradigms that include motivational interviewing, harm reduction, and social marketing in order to create an open dialogue that invites honest answers, focuses on individual strengths and goals, builds skills, and promotes personal responsibility. Use of the following principles to guide discussions of adolescent sexuality facilitates promotion of individual strengths and responsibility while reducing potentially negative consequences:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confidentiality",
"     </li>",
"     <li>",
"      Normalization",
"     </li>",
"     <li>",
"      Respect",
"     </li>",
"     <li>",
"      Avoid assumptions",
"     </li>",
"     <li>",
"      Specific questioning",
"     </li>",
"     <li>",
"      Listen to responses",
"     </li>",
"     <li>",
"      Avoid medical jargon",
"     </li>",
"     <li>",
"      Help the adolescent recognize the links between sexual risk taking and other aspects of their lives",
"     </li>",
"     <li>",
"      Think about prevention",
"     </li>",
"     <li>",
"      Know community resources",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Confidentiality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assuring confidentiality is the first step in establishing basic trust and respect between the medical provider and the adolescent patient. Most adolescents require absolute privacy to talk candidly about their sexuality. Always ask partners, friends, or parents to leave the examination room at some point during the visit and before beginning these discussions. The importance of confidentiality in caring for adolescent patients, particularly surrounding issues of sexuality, cannot be overemphasized. This is especially true for lesbian, gay, bisexual, transgender, queer, or questioning youth who may fear lack of sensitive or appropriate care as well as being inadvertently \"outed\" by their health care provider to parents or peers, an event that can have a significant effect on the sexual minority youth's family relationships, social status, and personal safety [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/79\">",
"     79",
"    </a>",
"    ]. Concerns about confidentiality are cited frequently as a reason to avoid seeking health care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before initiating a discussion about confidentiality, health care providers must be careful to understand both state and institutional boundaries surrounding this issue, particularly with respect to treating adolescents without parental consent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=see_link\">",
"     \"Consent in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Normalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because many adolescents do not have experience in answering questions of a sexual nature, the role of the clinician is to normalize discussions of sex. In order to do so, clinicians must be comfortable asking questions about sexuality and sexual behavior themselves. If health care providers appear uncomfortable asking questions about condom use or sexual orientation, the adolescent patient certainly will not feel comfortable answering them. It is important for health care providers to develop a communication style that enables them to ask the questions and get the answers they need to provide patients with appropriate health care, education, support, and referral. The discussion should take place when the patient is dressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Respect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care facilities and individual providers must have respect for the diversity and differences inherent in adolescents and young adults, including gender,",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    sexual orientation, and physical appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/80\">",
"     80",
"    </a>",
"    ]. Respect begins with front desk staff and waiting room material. It is demonstrated by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staff who are interested in seeing adolescents and skilled in the basics of providing adolescent health care",
"     </li>",
"     <li>",
"      Brochures, posters, pamphlets, and other information that is welcoming to all youth",
"     </li>",
"     <li>",
"      Clinic materials, administrative intake, and nursing triage that is inclusive of a wide variety of gender and sexual diversity",
"     </li>",
"     <li>",
"      The use of open, non-judgmental questions and avoidance of terms that could be perceived a pejorative such as &ldquo;casual sex&rdquo; or &ldquo;multiple sexual partners&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Avoid assumptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for health care providers to avoid making assumptions about the sexuality of their adolescent patients. In particular, health care providers should",
"    <strong>",
"     not",
"    </strong>",
"    assume:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      That all patients are heterosexual unless told otherwise [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/22,81\">",
"       22,81",
"      </a>",
"      ]. Gay, lesbian, and bisexual youth exist in all communities and in all pediatric practices; health care providers should ask adolescents questions that are gender and sexuality neutral. Avoid terms such as \"boyfriend\" or \"girlfriend\" but instead ask about \"crushes\" or \"romantic or sexual partners\", directly asking if patients are attracted to males, females, both, or neither. Open questions and gender-neutral questions allow the adolescent to reveal the gender of their partners and begin a conversation about sexual identity and sexual behaviors.",
"     </li>",
"     <li>",
"      That males who self-identify as heterosexual do not also have same-gender sexual partners. Particularly in communities of color, young men who have sex with men may self-identify as heterosexual and are at extremely high risk of acquiring HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      That a self-identified lesbian does not require birth control. Young women having sex with women may experiment with opposite-gender sexual partners and are at risk of becoming pregnant and acquiring STIs [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/82-85\">",
"       82-85",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      That patients with developmental delays or chronic illness are not sexually active and do not require the same anticipatory guidance as their peers without these problems [",
"      <a class=\"abstract\" href=\"UTD.htm?9/40/9866/abstract/86-89\">",
"       86-89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      That female adolescents do not engage in anal sex. Adolescent females may engage in anal sex as a pregnancy-prevention strategy and may not be aware of the need to use condoms for protection against HIV and STI.",
"     </li>",
"     <li>",
"      That patients have all the understanding and information they need about safer sexual practices. Providers should ask specifically what is meant by \"safer sex\", because their definition of this term may be different from what is thought by the adolescent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Specific questioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for health care providers to ask specific questions (",
"    <a class=\"graphic graphic_table graphicRef85699 \" href=\"UTD.htm?13/7/13438\">",
"     table 2",
"    </a>",
"    ). Questions such as, \"Are you sexually active?\" are closed-ended, vague, and open to multiple interpretations with regard to both time frame and type of sexual behavior. Some adolescents who engage in oral or anal sex may not consider themselves \"sexually active\" and, as such, may not be aware of the health risks associated with this behavior. Because health consequences resulting from sexual activity have more to do with sexual behavior than sexual orientation, questions should focus on:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Specific sexual behaviors",
"      </strong>",
"      &ndash; including digital, oral, vaginal, and anal intercourse. These questions should include information regarding date of last sexual activity, last sexual activity without a condom and without hormonal birth control. Detailed and specific information about behaviors and partners is important in determining risks and strengths. Sexual debut and lifetime, as well as recent, numbers of partners can be helpful components of a sexual risk assessment.",
"     </li>",
"     <li>",
"      <strong>",
"       Condom use",
"      </strong>",
"      &ndash; including how often and with whom. Separating condom use for STI prevention from condom use for contraception or family planning can be conceptually helpful and promotes use of dual methods for safer sex.",
"     </li>",
"     <li>",
"      <strong>",
"       Contraception",
"      </strong>",
"      &ndash; for themselves or their partner. Questions about current use, problems with prior methods including difficulties with adherence or continuation, fears or concerns about side effects and interest in other methods can generate useful discussion about contraceptive options. Asking directly about their immediate and long term family planning goals, including ambivalence about pregnancy, can provide additional useful information (",
"      <a class=\"graphic graphic_table graphicRef85698 \" href=\"UTD.htm?17/11/17596\">",
"       table 3",
"      </a>",
"      ). Including young heterosexual males in the screening and education process adds to their ability to contribute to family planning decisions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"       \"Contraception: Overview of issues specific to adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Victimization &ndash;",
"      </strong>",
"      coerced sex or \"sex against your will\" is common in adolescents and may be associated with other health issues including suicidal thoughts, substance use, and concerns about personal safety. Questions about exchanging sex for drugs, money, or housing may also be appropriate for homeless and disadvantaged youth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Listen to responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients deserve the undivided attention of their health care providers especially when discussing sensitive topics. Teens can be disconcerted and &ldquo;turned off&rdquo; to open and honest discussion of important sexual health issues if providers are perceived as either too busy, or worse, not interested. Providers who plan on providing adolescent sexual health services must plan to incorporate additional time and attention needed for sensitive and responsive screening and counseling. In addition, providers must pay attention to both verbal and nonverbal cues. Body language can be quite informative in interviews with adolescent patients, and an astute clinician might recognize opportunities for more in-depth questioning or targeted risk-prevention education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Avoid medical jargon",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for health care providers to speak about sexuality and sexual behavior in terms that are professional yet familiar and comfortable for the adolescent and avoid using medical jargon. As an example, questions about fellatio or cunnilingus may be replaced with more colloquial terms, such as \"oral sex\". For young men having sex with men, questions about anal insertive or anal receptive sex may be replaced with more familiar terms, such as \"top\" or \"bottom\", respectively. Developmentally appropriate terminology and focus is important for the early or developmentally delayed adolescent. Invariably, in discussions of sexuality, adolescents will use terminology or phrases that are not understood easily by the health care provider. In these cases, one should ask for clarification by stating, &ldquo;I am not familiar with that term. Can you tell me what you mean?&rdquo; Adolescents usually welcome the opportunity to talk about themselves and may see this request as an expression of interest on the part of the provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Recognize the links",
"    </span>",
"    &nbsp;&mdash;&nbsp;When talking with young people about sexuality and safer sex, an important factor is to help patients make connections between their sexual risk taking and other aspects of their lives. As an example, many youth engage in unsafe sexual practices while under the influence of drugs or alcohol. Helping an adolescent recognize this link is an important step in devising a comprehensive risk-reduction strategy that incorporates both substance-use services and safer sex practices. Other \"links\" include domestic violence, exchanging sex for money or drugs, and sexual assault. Each of these matters represents an opportunity for counseling, support, and referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Think prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young people have a lot of questions about their bodies and sexuality and have few safe, confidential spaces in which to ask about them. Whether it is a visit for a sore throat, abdominal pain, or yearly anticipatory guidance, each interaction can be seen by the health care provider as an opportunity for discussing health promotion and disease prevention. Just as providers discuss the importance of exercise or seat belts, or the health benefits of quitting smoking, they should provide sexuality education at every opportunity. It is important that disease prevention and contraception, including both condoms and hormonal methods, be readily available. No evidence suggests that the availability of contraception makes adolescents sexually active at younger ages than they would have been otherwise. Introducing sexuality in developmentally appropriate ways and while it is still relatively hypothetical is often welcomed by parents. Providers can model how to open discussions regarding sensitive topics as well as how to engage and counsel regarding safer sexual decision making.",
"   </p>",
"   <p>",
"    As an example: &ldquo;Well Sam, I am glad you and your dad are here together. During these adolescent health visits, we typically do some education about sexual health. Have you and your dad had any talks about puberty, dating, or sex? What have you and your dad talked about? It can be really hard for parents to think about their child having sex; just like it can be hard for teenagers to talk to their parents specifically about sex. It can be more comfortable to talk about sexuality and sexual health before there are any significant concerns. It is also really important to talk about sexual health and safety to prevent problems, diseases, unintended pregnancy, and unhealthy relationships.&rdquo;",
"   </p>",
"   <p>",
"    &ldquo;Let&rsquo;s talk about some common questions or concerns that people your age and a little older might have about sexual health. What is important for you (directed to the parent) to communicate about sex with your teen? From my perspective, it is important to discuss ways to enter into relationships safely and when you (directed to the teen) are ready for this. Picking a respectful and loving partner who listens to you and respects your limits is also important. We also want to make sure",
"    <span class=\"nowrap\">",
"     you/your",
"    </span>",
"    teen knows about how to avoid or prevent sexually transmitted infections. We want both boy and girl patients to consider ways to plan and prevent unintended pregnancy until they are ready to parent and raise a family.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Know community resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents may require or desire educational resources or other youth services that are beyond the scope of the individual practice setting. This need is particularly true for gay and lesbian youth. It is important to know what resources exist for youth in your community",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    state. In addition, a variety of Internet sites are available to provide relevant information and education on adolescent sexuality issues. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.aap.org\">",
"       American Academy of Pediatrics",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.iwannaknow.org/teens/index.html\">",
"       American Social Health Association",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nyacyouth.org/\">",
"       National Youth Advocacy Coalition",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.siecus.org/\">",
"       Sex Information and Education Council of the United States",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://teenshealth.org/teen/\">",
"       Nemours Foundation",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/21/1363?source=see_link\">",
"       \"Patient information: Teen sexuality (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       \"Patient information: Normal sexual development (puberty) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/8/35973?source=see_link\">",
"       \"Patient information: Adolescent sexuality (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human sexuality is a broad concept that embodies interaction among anatomy, biology, psychology, interpersonal relationships, and sociocultural influences. Sexuality, sexual behaviors, and sexual relationships are an important and necessary part of human development. &ldquo;Responsible sexual behavior&rdquo; (eg, delaying initiation of sexual intercourse, choosing caring and respectful partners, increasing the use of condoms, and using effective contraception) is an important public health issue. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adolescent development is frequently divided into three stages based loosely on chronologic age and level of functioning: early, middle, and late adolescence (",
"      <a class=\"graphic graphic_table graphicRef79899 \" href=\"UTD.htm?38/28/39371\">",
"       table 1",
"      </a>",
"      ). One of the tasks for healthy adolescent development is the acquisition of a mature and responsible sexuality including both an expression of sexual behaviors and the capacity for meaningful intimate relationships. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adolescent development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health care providers are a valued and trusted source of information and advice about adolescent health and sexuality. It is important for them to take advantage of opportunities to discuss sexual behavior, particularly as it pertains to the prevention of pregnancy and sexually transmitted infections. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Health care provider issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Health issues and outcomes related to sexuality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When discussing sexuality and sexual behavior with adolescents, it is important to create an open dialogue that invites honest answers, focuses on individual strengths and goals, builds skills, and promotes personal responsibility, while reducing the risk of potentially negative consequences (",
"      <a class=\"graphic graphic_table graphicRef85699 \" href=\"UTD.htm?13/7/13438\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef85698 \" href=\"UTD.htm?17/11/17596\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Principles of care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Healthy People 2020. Family Planning. file://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=13 (Accessed on September 19, 2011).",
"    </li>",
"    <li>",
"     Healthy People 2020. Sexually Transmitted Diseases. file://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=37 (Accessed on September 19, 2011).",
"    </li>",
"    <li>",
"     Adolescent Friendly Health Services: An Agenda for Change. The World Health Organization 2004. www.who.int/child_adolescent_health/documents/fch_cah_02_14/en/index.html (Accessed on September 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/4\">",
"      Mbizvo MT, Zaidi S. Addressing critical gaps in achieving universal access to sexual and reproductive health (SRH): the case for improving adolescent SRH, preventing unsafe abortion, and enhancing linkages between SRH and HIV interventions. Int J Gynaecol Obstet 2010; 110 Suppl:S3.",
"     </a>",
"    </li>",
"    <li>",
"     UNFPA. Generation of Change: Young People and Culture, Youth Supplement: State of World Population 2008, UNFPA, New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/6\">",
"      Euling SY, Herman-Giddens ME, Lee PA, et al. Examination of US puberty-timing data from 1940 to 1994 for secular trends: panel findings. Pediatrics 2008; 121 Suppl 3:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/7\">",
"      Chandra A, Mosher WD, Copen C, Sionean C. Sexual behavior, sexual attraction, and sexual identity in the United States: data from the 2006-2008 National Survey of Family Growth. Natl Health Stat Report 2011; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/8\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/9\">",
"      Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/10\">",
"      Kann L, Olsen EO, McManus T, et al. Sexual identity, sex of sexual contacts, and health-risk behaviors among students in grades 9-12--youth risk behavior surveillance, selected sites, United States, 2001-2009. MMWR Surveill Summ 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/11\">",
"      Remafedi G, Resnick M, Blum R, Harris L. Demography of sexual orientation in adolescents. Pediatrics 1992; 89:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/12\">",
"      Pathela P, Schillinger JA. Sexual behaviors and sexual violence: adolescents with opposite-, same-, or both-sex partners. Pediatrics 2010; 126:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/13\">",
"      Adolescent Health Updated Editorial Board. Use a strengths-based approach to adolescent preventive care. AAP News 2009; 30:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/14\">",
"      Brown RT. Adolescent sexuality at the dawn of the 21st century. Adolesc Med 2000; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/15\">",
"      Cohen-Kettenis PT, Gooren LJ. Transsexualism: a review of etiology, diagnosis and treatment. J Psychosom Res 1999; 46:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/16\">",
"      Frankowski BL, American Academy of Pediatrics Committee on Adolescence. Sexual orientation and adolescents. Pediatrics 2004; 113:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/17\">",
"      Meyer W, Bockting WP, Cohen-Kettenis E, et al. The Harry Benjamin International Gender Dysphoria Association: Standards of care for gender identity disorders. Int J Transgender 2001; 5.",
"     </a>",
"    </li>",
"    <li>",
"     Transgender Health Program, Guidelines for Transgender Care. Vancouver Coastal Health. file://transhealth.vch.ca/resources/careguidelines.html (Accessed on June 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/19\">",
"      Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.",
"     </a>",
"    </li>",
"    <li>",
"     Zucker KJ, Cohen-Kettenis PT. Gender identity disorder in children and adolescents. In: Handbook of Sexual and Gender Identity Disorders, Rowland DL, Incrocci L.  (Eds), Wiley, Hoboken, NJ 2008. p.376.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/21\">",
"      Igartua K, Thombs BD, Burgos G, Montoro R. Concordance and discrepancy in sexual identity, attraction, and behavior among adolescents. J Adolesc Health 2009; 45:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/22\">",
"      McCabe J, Brewster KL, Tillman KH. Patterns and correlates of same-sex sexual activity among U.S. teenagers and young adults. Perspect Sex Reprod Health 2011; 43:142.",
"     </a>",
"    </li>",
"    <li>",
"     Kinsey AC, Pomeroy WB, Martin CE. Sexual behavior in the human male, WB Saunders, Philadelphia 1948.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/24\">",
"      Moore RE. Normal childhood and early adolescent sexuality. A psychologist's perspective. Semin Adolesc Med 1985; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/25\">",
"      Savic I, Garcia-Falgueras A, Swaab DF. Sexual differentiation of the human brain in relation to gender identity and sexual orientation. Prog Brain Res 2010; 186:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/26\">",
"      Strasburger VC, Jordan AB, Donnerstein E. Health effects of media on children and adolescents. Pediatrics 2010; 125:756.",
"     </a>",
"    </li>",
"    <li>",
"     Rideout VJ, Foehr UG, Roberts DF. Generation M2: Media in the lives of 8- to 18-Year-Olds, Kaiser Family Foundation, Menlo Park, CA 2010.",
"    </li>",
"    <li>",
"     Kunkel D, Eyal K, Finnerty K, et al. Sex on TV 4: A Biennial Report to the Kaiser Family Foundation, Kaiser Family Foundation, Menlo Park, CA 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/29\">",
"      Kunkel D, Eyal K, Donnerstein E, et al. Sexual socialization messages on entertainment television. Media Psychol 2007; 9:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/30\">",
"      Braun-Courville DK, Rojas M. Exposure to sexually explicit Web sites and adolescent sexual attitudes and behaviors. J Adolesc Health 2009; 45:156.",
"     </a>",
"    </li>",
"    <li>",
"     Stern S. Sexual selves on the World Wide Web: Adolescent girls' home pages as sites for sexual self-expression. In: Sexual Teens, Sexual Media: Investigating Media's Influence on Adolescent Sexuality, Brown JD, Steele JR, Walsh-Childers K.  (Eds), Lawrence Erlbaum Associates, Inc., Mahwah, NJ 2002. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/32\">",
"      Moreno MA, Parks MR, Zimmerman FJ, et al. Display of health risk behaviors on MySpace by adolescents: prevalence and associations. Arch Pediatr Adolesc Med 2009; 163:27.",
"     </a>",
"    </li>",
"    <li>",
"     National Campaign to Prevent Teen and Unplanned Pregnancy, 2008. Sex and Tech: Results from a survey of teens and young adults file://www.thenationalcampaign.org/sextech/pdf/sextech_summary.pdf (Accessed on July 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/34\">",
"      Hatzenbuehler ML. The social environment and suicide attempts in lesbian, gay, and bisexual youth. Pediatrics 2011; 127:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/35\">",
"      Eisenberg ME, Resnick MD. Suicidality among gay, lesbian and bisexual youth: the role of protective factors. J Adolesc Health 2006; 39:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/36\">",
"      Rew L, Whittaker TA, Taylor-Seehafer MA, Smith LR. Sexual health risks and protective resources in gay, lesbian, bisexual, and heterosexual homeless youth. J Spec Pediatr Nurs 2005; 10:11.",
"     </a>",
"    </li>",
"    <li>",
"     The Guidelines for Comprehensive Sexuality Education: Grades K-12. Sexuality Information and Education Council of the United States. www.siecus.org/_data/global/images/guidelines.pdf (Accessed on July 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/38\">",
"      Song AV, Halpern-Felsher BL. Predictive relationship between adolescent oral and vaginal sex: results from a prospective, longitudinal study. Arch Pediatr Adolesc Med 2011; 165:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/39\">",
"      Biddlecom AE. Trends in sexual behaviours and infections among young people in the United States. Sex Transm Infect 2004; 80 Suppl 2:ii74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/40\">",
"      Turner CF, Ku L, Rogers SM, et al. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science 1998; 280:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/41\">",
"      Hewitt M. Attitudes toward interview mode and comparability of reporting sexual behavior by personal interview and audio computer-assisted self-interviewing: analyses of the 1995 National Survey of Family Growth. Sociol Methods Res 2002; 31:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/42\">",
"      Fu H, Darroch JE, Henshaw SK, Kolb E. Measuring the extent of abortion underreporting in the 1995 National Survey of Family Growth. Fam Plann Perspect 1998; 30:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/43\">",
"      DiClemente RJ, Sales JM, Danner F, Crosby RA. Association between sexually transmitted diseases and young adults' self-reported abstinence. Pediatrics 2011; 127:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/44\">",
"      Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/45\">",
"      Frost JJ, Darroch JE. Factors associated with contraceptive choice and inconsistent method use, United States, 2004. Perspect Sex Reprod Health 2008; 40:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/46\">",
"      Sheeder J, Teal SB, Crane LA, Stevens-Simon C. Adolescent childbearing ambivalence: is it the sum of its parts? J Pediatr Adolesc Gynecol 2010; 23:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/47\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol 2007; 110:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/48\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/49\">",
"      Forhan SE, Gottlieb SL, Sternberg MR, et al. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics 2009; 124:1505.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine (IOM). Adolescent Health Services: Missing Opportunities, The National Academies Press, Washington, DC 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/51\">",
"      Henry-Reid LM, O'Connor KG, Klein JD, et al. Current pediatrician practices in identifying high-risk behaviors of adolescents. Pediatrics 2010; 125:e741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/52\">",
"      Teten AL, Ball B, Valle LA, et al. Considerations for the definition, measurement, consequences, and prevention of dating violence victimization among adolescent girls. J Womens Health (Larchmt) 2009; 18:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/53\">",
"      Miller E, Decker MR, Raj A, et al. Intimate partner violence and health care-seeking patterns among female users of urban adolescent clinics. Matern Child Health J 2010; 14:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/54\">",
"      Cutter-Wilson E, Richmond T. Understanding teen dating violence: practical screening and intervention strategies for pediatric and adolescent healthcare providers. Curr Opin Pediatr 2011; 23:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/55\">",
"      Coker TR, Austin SB, Schuster MA. The health and health care of lesbian, gay, and bisexual adolescents. Annu Rev Public Health 2010; 31:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/56\">",
"      Kalichman SC, Benotsch E, Rompa D, et al. Unwanted Sexual Experiences and Sexual Risks in Gay and Bisexual Men: Associations among Revictimization, Substance Use, and Psychiatric Symptoms. J Sex Res 2001; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/57\">",
"      Halpern CT. Same-sex attraction and health disparities: do sexual minority youth really need something different for healthy development? J Adolesc Health 2011; 48:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/58\">",
"      Constantine NA. Converging evidence leaves policy behind: sex education in the United States. J Adolesc Health 2008; 42:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/59\">",
"      Kohler PK, Manhart LE, Lafferty WE. Abstinence-only and comprehensive sex education and the initiation of sexual activity and teen pregnancy. J Adolesc Health 2008; 42:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/60\">",
"      Eisenberg ME, Bernat DH, Bearinger LH, Resnick MD. Support for comprehensive sexuality education: perspectives from parents of school-age youth. J Adolesc Health 2008; 42:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/61\">",
"      Ott MA, Santelli JS. Approaches to adolescent sexuality education. Adolesc Med State Art Rev 2007; 18:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/62\">",
"      Kirby D, Laris BA. Effective curriculum-based sex and STD/HIV education programs for adolescents. Child Dev Perspect 2009; 3:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/63\">",
"      Kantor L, Santelli J, Teitler J, Balmer R. Abstinence-Only Policies and Programs: An Overview. Sex Res Soc Pol 2008; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/64\">",
"      Johnson BT, Scott-Sheldon LA, Huedo-Medina TB, Carey MP. Interventions to reduce sexual risk for human immunodeficiency virus in adolescents: a meta-analysis of trials, 1985-2008. Arch Pediatr Adolesc Med 2011; 165:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/65\">",
"      Shepherd J, Kavanagh J, Picot J, et al. The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19: a systematic review and economic evaluation. Health Technol Assess 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     Kirby D. Research Findings on Programs to Reduce Teen Pregnancy, The National Campaign to Prevent Teen Pregnancy, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/67\">",
"      Inman DD, van Bakergem KM, Larosa AC, Garr DR. Evidence-based health promotion programs for schools and communities. Am J Prev Med 2011; 40:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/68\">",
"      Rupp R, Rosenthal SL. Parental influences on adolescent sexual behaviors. Adolesc Med State Art Rev 2007; 18:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/69\">",
"      Council on Communications and Media. American Academy of Pediatrics. Policy statement--sexuality, contraception, and the media. Pediatrics 2010; 126:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/70\">",
"      Strasburger VC. Adolescents, sex, and the media: ooooo, baby, baby-a Q &amp; A. Adolesc Med Clin 2005; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/71\">",
"      Bleakley A, Hennessy M, Fishbein M, Jordan A. How sources of sexual information relate to adolescents' beliefs about sex. Am J Health Behav 2009; 33:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/72\">",
"      Schuster MA, Corona R, Elliott MN, et al. Evaluation of Talking Parents, Healthy Teens, a new worksite based parenting programme to promote parent-adolescent communication about sexual health: randomised controlled trial. BMJ 2008; 337:a308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/73\">",
"      Bailey JV, Murray E, Rait G, et al. Interactive computer-based interventions for sexual health promotion. Cochrane Database Syst Rev 2010; :CD006483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/74\">",
"      Gold J, Lim MS, Hellard ME, et al. What's in a message? Delivering sexual health promotion to young people in Australia via text messaging. BMC Public Health 2010; 10:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/75\">",
"      Gold J, Lim MS, Hocking JS, et al. Determining the impact of text messaging for sexual health promotion to young people. Sex Transm Dis 2011; 38:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/76\">",
"      Kavanaugh ML, Schwarz EB. Counseling about and use of emergency contraception in the United States. Perspect Sex Reprod Health 2008; 40:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/77\">",
"      Brown JD, Strasburger VC. From Calvin Klein to Paris Hilton and MySpace: adolescents, sex, and the media. Adolesc Med State Art Rev 2007; 18:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/78\">",
"      Tylee A, Haller DM, Graham T, et al. Youth-friendly primary-care services: how are we doing and what more needs to be done? Lancet 2007; 369:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/79\">",
"      Ogle S, Glasier A, Riley SC. Communication between parents and their children about sexual health. Contraception 2008; 77:283.",
"     </a>",
"    </li>",
"    <li>",
"     The Health of Lesbian, Gay, Bisexual, and Transgender People Building a Foundation for Better Understanding. Committee on Lesbian, Gay, Bisexual, and Transgender Health Issues and Research Gaps and Opportunities. Board on the Health of Select Populations. Institute of Medicine of the National Academies. htttp://www.nap.edu/openbook.php?record_id=13128&amp;page=R1 (Accessed on July 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/81\">",
"      East JA, El Rayess F. Pediatricians' approach to the health care of lesbian, gay, and bisexual youth. J Adolesc Health 1998; 23:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/82\">",
"      Diamant AL, Schuster MA, McGuigan K, Lever J. Lesbians' sexual history with men: implications for taking a sexual history. Arch Intern Med 1999; 159:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/83\">",
"      Marrazzo JM, Koutsky LA, Kiviat NB, et al. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001; 91:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/84\">",
"      Saewyc EM, Bearinger LH, Blum RW, Resnick MD. Sexual intercourse, abuse and pregnancy among adolescent women: does sexual orientation make a difference? Fam Plann Perspect 1999; 31:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/85\">",
"      Bailey JV, Farquhar C, Owen C. Bacterial vaginosis in lesbians and bisexual women. Sex Transm Dis 2004; 31:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/86\">",
"      Greydanus DE, Omar HA. Sexuality issues and gynecologic care of adolescents with developmental disabilities. Pediatr Clin North Am 2008; 55:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/87\">",
"      Ward KM, Bosek RL, Trimble EL. Romantic relationships and interpersonal violence among adults with developmental disabilities. Intellect Dev Disabil 2010; 48:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/88\">",
"      Tice CJ, Hall DM. Sexuality education and adolescents with developmental disabilities: assessment, policy, and advocacy. J Soc Work Disabil Rehabil 2008; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/40/9866/abstract/89\">",
"      Rew L. Sexual health of adolescents with chronic health conditions. Adolesc Med State Art Rev 2007; 18:519.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 113 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9866=[""].join("\n");
var outline_f9_40_9866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Biologic, anatomic, or natal sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sexual orientation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8879340\">",
"      SEXUALITY AND SOCIETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADOLESCENT DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Early adolescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Middle adolescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Late adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEALTH ISSUES AND OUTCOMES RELATED TO SEXUALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      STIs and HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45216050\">",
"      Sexual victimization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45216087\">",
"      - Teen dating violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H45216032\">",
"      Sexual minority youth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEALTH CARE PROVIDER ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sex education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Barriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Principles of care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Confidentiality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Normalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Respect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Avoid assumptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Specific questioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Listen to responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Avoid medical jargon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Recognize the links",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Think prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Know community resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/113\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/113|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/46/39649\" title=\"figure 1\">",
"      Paradigm of sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/113|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/28/39371\" title=\"table 1\">",
"      Adolescent development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/7/13438\" title=\"table 2\">",
"      Discussing adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/11/17596\" title=\"table 3\">",
"      Discussing contraception with adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=related_link\">",
"      Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=related_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15561?source=related_link\">",
"      Date rape: Identification and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33385?source=related_link\">",
"      Date rape: Risk factors and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=related_link\">",
"      Diagnosis and treatment of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=related_link\">",
"      Guidelines for adolescent preventive services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=related_link\">",
"      Management of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/8/35973?source=related_link\">",
"      Patient information: Adolescent sexuality (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/21/1363?source=related_link\">",
"      Patient information: Teen sexuality (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/31/10744?source=related_link\">",
"      Pregnancy in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=related_link\">",
"      Steroid 5-alpha-reductase 2 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1737?source=related_link\">",
"      The adolescent with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=related_link\">",
"      Transsexualism: Epidemiology, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_40_9867="CT EUS and EUS-FNA for esoph cancer staging";
var content_f9_40_9867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prospective comparison of CT, EUS and EUS FNA for preoperative lymph node staging of esophageal carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT",
"       </td>",
"       <td>",
"        29 (17 to 44)",
"       </td>",
"       <td>",
"        89 (72 to 98)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EUS",
"       </td>",
"       <td>",
"        71 (56 to 83)",
"       </td>",
"       <td>",
"        79 (59 to 92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EUS FNA",
"       </td>",
"       <td>",
"        83 (70 to 93)",
"       </td>",
"       <td>",
"        93 (77 to 99)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; EUS: endoscopic ultrasound; FNA: fine-needle aspiration.",
"     <br>",
"      * Data shown represent percentages (95% CI).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vazquez-Sequeiros, E, Clain, JE, Norton, ID, et al, Gastroenterology 2003; 125:1626.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9867=[""].join("\n");
var outline_f9_40_9867=null;
var title_f9_40_9868="Common factors bad breath";
var content_f9_40_9868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some common factors exacerbating bad breath",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Accumulation of postnasal drip on the posterior of the tongue dorsum (in children and adults)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Poor oral hygiene (particularly failure to clean between the teeth with floss or an interdental brush)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Improper dental care  (eg, faulty bridgework, leaking crowns, abscesses)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mouth breathing and other causes of dry mouth (eg, fasting, medications, prolonged speech, long time between meals, and stress and anxiety)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unclean dentures (eg, left in mouth unnecessarily during the night)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcohol consumption",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Being overweight",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Menstrual cycle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Proteinaceous foods that get stuck between the teeth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Onions and garlic",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Rosenberg, M. Introduction: In: Bad Breath: Research Perspectives, Rosenberg, M (Ed), Ramot Publishing, Tel Aviv University 1995. p.1.",
"      <br>",
"       Rosenberg, M. Clinical assessment of bad breath: current concepts. J Am Dent Assoc 1996; 127:475.",
"       <br>",
"        Amir, E, Shimonov, R, Rosenberg, M. Halitosis in children. J Pediatr 1999; 134:338.",
"        <br>",
"         Tonzetich, J. Oral malodour: an indicator of health status and oral cleanliness. Int Dent J 1978; 28:309.",
"         <br>",
"          Scully, C, Porter, S, Greenman, J. What to do about halitosis. BMJ 1994; 308:217.",
"          <br>",
"           Calil, CM, Marcondes, FK. Influence of anxiety on the production of oral volatile sulfur compounds. Life Sci 2006; 79:660.",
"           <br>",
"            Rosenberg, M, Kulkarni, GV, Bosy, A, McCulloch, CA. Reproducibility and sensitivity of oral malodor measurements with a portable sulphide monitor. J Dent Res 1991; 70:1436.",
"            <br>",
"             Knaan, T, Cohen, D, Rosenberg, M. Predicting bad breath in the noncomplaining population. Oral Dis 2005; 11:105.",
"             <br>",
"              Tonzetich, J, Preti, G, Huggins, GR. Changes in concentration of volatile sulphur compounds of mouth air during the menstrual cycle. J Int Med Res 1978; 6:245.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9868=[""].join("\n");
var outline_f9_40_9868=null;
var title_f9_40_9869="Initiating Rx 0 to 4 yrs";
var content_f9_40_9869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity and initiating treatment in children 0 to 4 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (0 to 4 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1 to 2x/month",
"       </td>",
"       <td>",
"        3 to 4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic glucocorticoids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0 to 1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2 exacerbations in six months requiring oral systemic glucocorticoids, or &ge;4 wheezing episodes/one year lasting &gt;1 day AND risk factors for persistent asthma",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Exacerbations of any severity may occur in patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\" rowspan=\"2\">",
"        Recommended step for initiating treatment",
"       </td>",
"       <td>",
"        Step 1",
"       </td>",
"       <td>",
"        Step 2",
"       </td>",
"       <td colspan=\"2\">",
"        Step 3 and consider short course of oral systemic glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        In two to six weeks, depending on severity, evaluate level of asthma control that is achieved. If no clear benefit is observed in four to six weeks, consider adjusting therapy or alternative diagnoses.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Assessing severity and initiating therapy in children who are not currently taking long-term control medication.",
"    </strong>",
"    The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous two to four weeks. Symptom assessment for longer periods should reflect a global assessment such as inquiring whether the patient's asthma is better or worse since the last visit. Assign severity to the most severe category in which any feature occurs. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past six months, or &ge;4 wheezing episodes in the past year, and who have risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9869=[""].join("\n");
var outline_f9_40_9869=null;
var title_f9_40_9870="Thyroid hormone action part A";
var content_f9_40_9870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Mediation of thyroid hormone action",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 205px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the absence of T3, thyroid hormone receptor (TR) heterodimerizes with retinoid X receptor (RXR), binds to a thyroid hormone response element (TRE) and recruits co-repressor (CoR), resulting in gene silencing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Refetoff S, Weiss RE. Resistance to thyroid hormone. In: Molecular Genetics of Endocrine Disorders, Thakker TV (Ed), Chapman &amp; Hill, London, 1997, p.89.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9870=[""].join("\n");
var outline_f9_40_9870=null;
var title_f9_40_9871="Syphilitic aortic aneurysm";
var content_f9_40_9871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest x-ray of tertiary cardiovascular syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The characteristic lesion is a fusiform aneurysm of the thoracic aorta which almost always involving the ascending arch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_40_9871=[""].join("\n");
var outline_f9_40_9871=null;
